UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☑			Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period Ended October ~~2, 2022~~1, 2023


☐			Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number 001-35406

Illumina, Inc.

(Exact name of registrant as specified in its charter)


Delaware						33-0804655
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

5200 Illumina Way, San Diego, CA 92122

(Address of principal executive offices) (Zip code)

(858) 202-4500

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	ILMN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

As of ~~October 28, 2022,~~November 6, 2023, there were ~~157.3~~158.8 million shares of the registrant’s common stock outstanding.

Table of Contents

ILLUMINA, INC.

FORM 10-Q

FOR THE FISCAL QUARTER ENDED OCTOBER ~~2, 2022~~1, 2023

TABLE OF CONTENTS

See “Form 10-Q Cross-Reference Index” within Other Key Information for a cross-reference to the parts and items requirements of the Securities and Exchange Commission Quarterly Report on Form 10-Q.


CONDENSED CONSOLIDATED FINANCIAL STATEMENTS			PAGE
Condensed Consolidated Balance Sheets			6
Condensed Consolidated Statements of Operations			7
Condensed Consolidated Statements of Comprehensive ~~Income (Loss)~~Loss			8
Condensed Consolidated Statement s of Stockholders’ Equity			9
Condensed Consolidated Statements of Cash Flows			11
Notes to Condensed Consolidated Financial Statements			12
1. Organization and Significant Accounting Policies			12
2. Revenue			1413
3. Investments and Fair Value Measurements			1514

4. Debt			17
5. Stockholders’ Equity			2019
6. Supplemental Balance Sheet Details			22
7. Legal Proceedings			25
8. Income Taxes			2927
9. Segment Information			2928


MANAGEMENT’S DISCUSSION & ANALYSIS
Management’s Overview and Outlook			3129
Results of Operations			3331
Liquidity and Capital Resources			3736
Critical Accounting Policies and Estimates			4038
Recent Accounting Pronouncements			4039

Quantitative and Qualitative Disclosures About Market Risk			4039

OTHER KEY INFORMATION
Controls and Procedures			4039
Legal Proceedings			4039
Risk Factors			4039
Share Repurchases and Sales			4342
Adoptions, Modifications or Terminations of Trading Plans			42
Exhibits			4443
Form 10-Q Cross-Reference Index			4544

Table of Contents

Consideration Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “continue,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “potential,” “predict,” “should,” “will,” or similar words or phrases, or the negatives of these words, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward looking. Examples of forward-looking statements include, among others, statements we make regarding:

•our expectations as to our future financial performance, results of operations, or other operational results or metrics;

•~~our expectations regarding the launch of new products or services;~~

•the benefits that we expect will result from our business activities and certain transactions we have completed, or may complete, such as product introductions, increased revenue, decreased expenses, and avoided expenses and expenditures;

•our expectations of the effect on our financial condition of claims, litigation, contingent liabilities, and governmental investigations, proceedings, and regulations;

•our strategies or expectations for product development, market position, financial results, and reserves;

•our ability to successfully implement cost reduction plans in a timely manner and the possibility that costs associated with our cost reduction plans are greater than we anticipate;

•our expectations regarding the outcome of the legal and regulatory proceedings, including ~~any related~~ appeals, related to our acquisition of GRAIL, Inc. (GRAIL) and other actions that may be taken or pursued by the European Commission, the U.S. Federal Trade Commission (FTC) and/or other governmental or regulatory authorities in connection with such acquisition;

•the ~~interim~~transitional measures ~~order~~ imposed by the European Commission, the duration and impact of such ~~order~~measures on Illumina and GRAIL, and the appointment of a monitoring trustee to monitor our compliance with such ~~order;~~measures;

•the prohibition decision adopted by the European Commission on September 6, 2022 (the Prohibition Decision), informing us of its decision to prohibit our acquisition of GRAIL, and the ~~public statements made by the European Commission in connection with such~~ decision ~~that indicate that a subsequent decision is likely to be~~ adopted by the European Commission ~~that will~~on October 12, 2023 requiring us to (among other things) divest GRAIL and imposing transitional measures (the EC Divestment Decision);

•the opinion and order issued by the FTC on March 31, 2023 (the FTC Order), requiring us to divest ~~GRAIL;~~GRAIL and to hold GRAIL separate through the completion of the divestiture;

•~~our expectations regarding~~ the ~~integration of any acquired technologies with our existing technology;~~Article 14(2)(b) fine imposed by the European Commission on July 12, 2023; and

•other expectations, beliefs, plans, strategies, anticipated developments, and other matters that are not historical facts.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

•~~the impact to our business and operating results caused by the COVID-19 pandemic;~~

•our expectations and beliefs regarding prospects and growth for our business and the markets in which we operate;

•the timing and mix of customer orders among our products and services;

Table of Contents

•challenges inherent in developing, manufacturing, and launching new products and services, including expanding manufacturing operations and reliance on third-party suppliers for critical components;

•the impact of recently launched or pre-announced products and services on existing products and services;

•~~our ability to develop and commercialize our instruments and consumables, to deploy new products, services, and applications, and to expand the markets for our technology platforms;~~

•~~our ability to manufacture robust instrumentation and consumables;~~

•~~our ability to identify and acquire technologies and integrate them into our products or businesses successfully;~~

•risks and uncertainties regarding the legal and regulatory proceedings, including the failure to obtain or delays in obtaining the required regulatory approvals or clearances including for any ~~related~~potential divestiture of GRAIL, any appeals relating to our acquisition of GRAIL and our ability to achieve the expected benefits of such acquisition and other actions that have been or may be taken or pursued by the European Commission, the ~~U.S. Federal Trade Commission~~FTC and/or other governmental or regulatory authorities in connection with such acquisition;

•the ~~interim~~transitional measures ~~order~~and hold separate requirements imposed by the European Commission, the duration and impact of ~~such order~~these requirements on Illumina and GRAIL ~~which impact~~(which may include material and adverse effects on ~~synergies and other~~ benefits we expect to achieve as a result of the acquisition of GRAIL, additional costs or liabilities, loss of revenue and other adverse effects on our business, financial condition and results of ~~operations;~~operations) and the administration of these requirements by an appointed monitoring trustee;

•our compliance with ~~the terms of the interim~~burdensome transitional measures ~~order~~ imposed by the European Commission ~~which is monitored by an appointed monitoring trustee, and which is burdensome to implement and administer,~~ and the risk that the European Commission could impose or seek to impose additional fines and other penalties for alleged noncompliance with ~~such terms;~~these requirements;

•the ~~possibility that we~~EC Divestment Decision and the FTC Order, which may ~~be required~~each adversely affect us and our business, including current plans and operations, financial condition and results of operations, each requiring us to divest GRAIL and to hold GRAIL separate through the completion of the divestiture, the terms and conditions ~~of any required~~thereof (including with respect to a divestiture of ~~GRAIL,~~GRAIL), and the timing of and the risks, costs and business disruptions (including the diversion of management’s attention) associated with ~~any~~ such divestiture and/or any related appeals, the ~~announcement, pendency or~~ implementation thereof or any associated legal or regulatory proceedings or obligations, including any related appeals, and other uncertainties related to our compliance (or ability to comply) with ~~any order or decision regarding a divestiture~~each of ~~GRAIL,~~the EC Divestment Decision and the FTC Order, which may adversely affect us and our business, including current plans and operations, financial condition and results of operations;

•any negative effects of the announcement, pendency or implementation of the Prohibition Decision or any order or decision regarding a divestiture of GRAIL and/or of any divestiture of GRAIL on the market price of Illumina’s common stock and on Illumina’s operating results;

•risks associated with ~~third-party~~ contracts or other agreements containing provisions that might be implicated by any divestiture of GRAIL or the EC Divestment Decision, including our ability to fully realize the anticipated economic benefits of our commercial arrangements with GRAIL and our obligations with respect to ~~certain GRAIL~~ contingent value rights (the CVRs) issued by us in connection with the GRAIL acquisition and the risk that we will be unable to fully discharge such obligations in connection with a divestiture of ~~GRAIL;~~GRAIL, that a divestiture will result in a change in obligor on the CVRs and/or of other consequences related thereto, which may adversely affect us and our business and/or the market value of the CVRs;

•the risk of adverse effects resulting from additional potential litigation associated with the acquisition of ~~GRAIL;~~GRAIL, such as additional legal, financial advisory, regulatory and other professional services fees;

•the risk of additional litigation arising against us in connection with the GRAIL acquisition;

•the assumptions underlying our critical accounting policies and estimates;

•our assessments and estimates that determine our effective tax rate;

•our assessments and beliefs regarding the outcome of pending legal proceedings and any liability that we may incur as a result of those proceedings as well as the cost and potential diversion of management resources associated with these proceedings;

•uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth, ~~in the United States~~COVID-19 pandemic mitigation measures, or ~~worldwide;~~armed conflict; and

•other factors detailed in our filings with the Securities and Exchange Commission (SEC), including the risks, uncertainties, and assumptions described in “Risk Factors” within the Business & Market Information section of our Annual Report on Form 10-K for the fiscal year ended January 1, 2023, the “Other Key Information” section of our Quarterly Report on Form 10-Q for the period ended April 2, ~~2022, the~~2023

Table of Contents

~~“Other Key Information” section of our Quarterly Report~~and on Form 10-Q for the period ended ~~April 3, 2022,~~July 2, 2023, the ~~Risk Factors~~“Risk Factors” section below, or in information disclosed in public conference calls, the date and time of which are released beforehand.

Any forward-looking statement made by us in this Quarterly Report on Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation, and do not intend, to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, or to review or confirm analysts’ expectations, or to provide interim reports or updates on the progress of any current financial quarter, in each case whether as a result of new information, future developments, or otherwise.

Table of Contents


CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

ILLUMINA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions)


		October 2, 2022		January 2, 2022			October 1, 2023		January 1, 2023
		(Unaudited)					(Unaudited)
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	1,000	$	1,232	Cash and cash equivalents	$	927	$	2,011
Short-term investments	Short-term investments	41		107		Short-term investments	6		26
Accounts receivable, net	Accounts receivable, net	628		648		Accounts receivable, net	690		671
Inventory, net	Inventory, net	559		431		Inventory, net	615		568

Prepaid expenses and other current assets	Prepaid expenses and other current assets	259		295		Prepaid expenses and other current assets	268		285
Total current assets	Total current assets	2,487		2,713		Total current assets	2,506		3,561
Property and equipment, net	Property and equipment, net	1,068		1,024		Property and equipment, net	1,040		1,091
Operating lease right-of-use assets	Operating lease right-of-use assets	680		672		Operating lease right-of-use assets	581		653
Goodwill	Goodwill	3,238		7,113		Goodwill	2,527		3,239
Intangible assets, net	Intangible assets, net	3,335		3,250		Intangible assets, net	3,029		3,285

Other assets	Other assets	448		445		Other assets	439		423
Total assets	Total assets	$	11,256	$	15,217	Total assets	$	10,122	$	12,252

LIABILITIES AND STOCKHOLDERS’ EQUITY	LIABILITIES AND STOCKHOLDERS’ EQUITY					LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	281	$	332	Accounts payable	$	240	$	293
Accrued liabilities	Accrued liabilities	1,142		761		Accrued liabilities	1,242		1,232

Term notes, current portion	Term notes, current portion	499		—		Term notes, current portion	—		500
Convertible senior notes, current portion	Convertible senior notes, current portion	747		—		Convertible senior notes, current portion	—		748
Total current liabilities	Total current liabilities	2,669		1,093		Total current liabilities	1,482		2,773
Operating lease liabilities	Operating lease liabilities	748		774		Operating lease liabilities	698		744
Term notes	Term notes	495		993		Term notes	1,489		1,487
Convertible senior notes		—		702

Other long-term liabilities	Other long-term liabilities	613		915		Other long-term liabilities	555		649

Stockholders’ equity:	Stockholders’ equity:					Stockholders’ equity:

Common stock	Common stock	2		2		Common stock	2		2
Additional paid-in capital	Additional paid-in capital	9,129		8,938		Additional paid-in capital	9,487		9,207
Accumulated other comprehensive income	Accumulated other comprehensive income	39		17		Accumulated other comprehensive income	21		3
Retained earnings	Retained earnings	1,281		5,485		Retained earnings	157		1,142
Treasury stock, at cost	Treasury stock, at cost	(3,720)		(3,702)		Treasury stock, at cost	(3,769)		(3,755)

Total stockholders’ equity	Total stockholders’ equity	6,731		10,740		Total stockholders’ equity	5,898		6,599
Total liabilities and stockholders’ equity	Total liabilities and stockholders’ equity	$	11,256	$	15,217	Total liabilities and stockholders’ equity	$	10,122	$	12,252

See accompanying notes to condensed consolidated financial statements.

Table of Contents

ILLUMINA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In millions, except per share amounts)


		Three Months Ended				Nine Months Ended					Three Months Ended				Nine Months Ended
		October 2, 2022		October 3, 2021		October 2, 2022		October 3, 2021			October 1, 2023		October 2, 2022		October 1, 2023		October 2, 2022
Revenue:	Revenue:									Revenue:
Product revenue	Product revenue	$	963	$	978	$	3,039	$	2,903	Product revenue	$	941	$	963	$	2,864	$	3,039
Service and other revenue	Service and other revenue	152		130		462		424		Service and other revenue	178		152		518		462
Total revenue	Total revenue	1,115		1,108		3,501		3,327		Total revenue	1,119		1,115		3,382		3,501
Cost of revenue:	Cost of revenue:									Cost of revenue:
Cost of product revenue	Cost of product revenue	280		264		866		782		Cost of product revenue	293		280		884		866
Cost of service and other revenue	Cost of service and other revenue	72		56		210		177		Cost of service and other revenue	95		72		285		210
Amortization of acquired intangible assets	Amortization of acquired intangible assets	46		18		125		31		Amortization of acquired intangible assets	47		46		143		125
Total cost of revenue	Total cost of revenue	398		338		1,201		990		Total cost of revenue	435		398		1,312		1,201
Gross profit	Gross profit	717		770		2,300		2,337		Gross profit	684		717		2,070		2,300
Operating expense:	Operating expense:									Operating expense:
Research and development	Research and development	325		436		975		835		Research and development	315		325		1,013		975
Selling, general and administrative	Selling, general and administrative	146		879		865		1,666		Selling, general and administrative	303		146		1,127		865
Goodwill and intangible impairment										Goodwill and intangible impairment	821		3,914		821		3,914
Legal contingency and settlement	Legal contingency and settlement	(11)		—		598		—		Legal contingency and settlement	(1)		(11)		14		598

Goodwill impairment		3,914		—		3,914		—
Total operating expense	Total operating expense	4,374		1,315		6,352		2,501		Total operating expense	1,438		4,374		2,975		6,352
Loss from operations	Loss from operations	(3,657)		(545)		(4,052)		(164)		Loss from operations	(754)		(3,657)		(905)		(4,052)
Other income (expense):	Other income (expense):									Other income (expense):
Interest income	Interest income	3		—		4		—		Interest income	13		3		47		4
Interest expense	Interest expense	(6)		(14)		(17)		(48)		Interest expense	(19)		(6)		(59)		(17)

Other (expense) income, net		(12)		979		(103)		1,010
Total other (expense) income, net		(15)		965		(116)		962
(Loss) income before income taxes		(3,672)		420		(4,168)		798
Provision for income taxes		144		103		97		148
Net (loss) income		$	(3,816)	$	317	$	(4,265)	$	650
Other expense, net										Other expense, net	(22)		(12)		(33)		(103)
Total other expense, net										Total other expense, net	(28)		(15)		(45)		(116)
Loss before income taxes										Loss before income taxes	(782)		(3,672)		(950)		(4,168)
(Benefit) provision for income taxes										(Benefit) provision for income taxes	(28)		144		36		97
Net loss										Net loss	$	(754)	$	(3,816)	$	(986)	$	(4,265)

(Loss) earnings per share:
Loss per share:										Loss per share:
Basic	Basic	$	(24.26)	$	2.09	$	(27.13)	$	4.39	Basic	$	(4.77)	$	(24.26)	$	(6.23)	$	(27.13)
Diluted	Diluted	$	(24.26)	$	2.08	$	(27.13)	$	4.36	Diluted	$	(4.77)	$	(24.26)	$	(6.23)	$	(27.13)
Shares used in computing (loss) earnings per share:
Shares used in computing loss per share:										Shares used in computing loss per share:
Basic	Basic	157		152		157		148		Basic	158		157		158		157
Diluted	Diluted	157		153		157		149		Diluted	158		157		158		157

See accompanying notes to condensed consolidated financial statements.

Table of Contents

ILLUMINA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE ~~INCOME (LOSS)~~LOSS

(Unaudited)

(In millions)


	Three Months Ended				Nine Months Ended
	October 1, 2023		October 2, 2022		October 1, 2023		October 2, 2022
Net loss	$	(754)	$	(3,816)	$	(986)	$	(4,265)

Unrealized gain on cash flow hedges, net of deferred tax	9		9		18		22
Total comprehensive loss	$	(745)	$	(3,807)	$	(968)	$	(4,243)

Three Months Ended Nine Months Ended
October 2,
2022 October 3,
2021 October 2,
2022 October 3,
2021
Net (loss) income $ (3,816) $ 317 $ (4,265) $ 650
Unrealized loss on available-for-sale debt securities, net of deferred tax — — — (1)
Unrealized gain on cash flow hedges, net of deferred tax 9 5 22 12
Total comprehensive (loss) income $ (3,807) $ 322 $ (4,243) $ 661

See accompanying notes to condensed consolidated financial statements.

Table of Contents

ILLUMINA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In millions)


				Additional		Accumulated Other							Total															Additional	Accumulated Other					Total
	Common Stock			Paid-In		Comprehensive		Retained		Treasury Stock			Stockholders’											Common Stock				Paid-In	Comprehensive	Retained		Treasury Stock		Stockholders’
	Shares	Amount		Capital		Income		Earnings		Shares	Amount		Equity											Shares		Amount		Capital	Income	Earnings		Shares	Amount	Equity

Balance as of January 3, 2021	195	$	2	$	3,815	$	2	$	4,723	(49)	$	(3,848)	$	4,694
Net income	—	—		—		—		147		—	—		147
Unrealized loss on available-for-sale debt securities, net of deferred tax	—	—		—		(1)		—		—	—		(1)
Unrealized gain on cash flow hedges, net of deferred tax	—	—		—		7		—		—	—		7
Issuance of common stock, net of repurchases	—	—		31		—		—		—	(24)		7
Share-based compensation	—	—		68		—		—		—	—		68
Balance as of April 4, 2021	195	2		3,914		8		4,870		(49)	(3,872)		4,922
Net income	—	—		—		—		185		—	—		185

Issuance of common stock, net of repurchases	1	—		—		—		—		—	(6)		(6)
Share-based compensation	—	—		79		—		—		—	—		79
Balance as of July 4, 2021	196	2		3,993		8		5,055		(49)	(3,878)		5,180
Net income	—	—		—		—		317		—	—		317

Unrealized gain on cash flow hedges, net of deferred tax	—	—		—		5		—		—	—		5
Issuance of common stock, net of repurchases	—	—		28		—		—		—	(2)		26
GRAIL acquisition	—	—		4,749		—		—		10	237		4,986

Share-based compensation	—	—		79		—		—		—	—		79
Balance as of October 3, 2021	196	2		8,849		13		5,372		(39)	(3,643)		10,593
Net income	—	—		—		—		113		—	—		113

Unrealized gain on cash flow hedges, net of deferred tax	—	—		—		4		—		—	—		4
Issuance of common stock, net of repurchases	1	—		1		—		—		(1)	(59)		(58)

Exchange of GRAIL contingent value rights	—	—		2		—		—		—	—		2
Share-based compensation	—	—		86		—		—		—	—		86
Balance as of January 2, 2022	197	$	2	$	8,938	$	17	$	5,485	(40)	$	(3,702)	$	10,740

Balance as of January 2, 2022															Balance as of January 2, 2022	197	$	2	$	8,938	$	17	$	5,485	(40)		$	(3,702)			$	10,740
Net income															Net income	—	—		—		—		86		—		—				86
Unrealized gain on cash flow hedges, net of deferred tax															Unrealized gain on cash flow hedges, net of deferred tax	—	—		—		1		—		—		—				1
Issuance of common stock, net of repurchases															Issuance of common stock, net of repurchases	—	—		33		—		—		—		(12)				21
Share-based compensation															Share-based compensation	—	—		79		—		—		—		—				79
Cumulative-effect adjustment from adoption of ASU 2020-06, net of deferred tax															Cumulative-effect adjustment from adoption of ASU 2020-06, net of deferred tax	—	—		(93)		—		61		—		—				(32)
Balance as of April 3, 2022															Balance as of April 3, 2022	197	2		8,957		18		5,632		(40)		(3,714)				10,895
Net loss															Net loss	—	—		—		—		(535)		—		—				(535)
Unrealized gain on cash flow hedges, net of deferred tax															Unrealized gain on cash flow hedges, net of deferred tax	—	—		—		12		—		—		—				12
Issuance of common stock, net of repurchases															Issuance of common stock, net of repurchases	—	—		—		—		—		—		(4)				(4)
Share-based compensation															Share-based compensation	—	—		76		—		—		—		—				76
Balance as of July 3, 2022															Balance as of July 3, 2022	197	2		9,033		30		5,097		(40)		(3,718)				10,444
Net loss															Net loss	—	—		—		—		(3,816)		—		—				(3,816)
Unrealized gain on cash flow hedges, net of deferred tax															Unrealized gain on cash flow hedges, net of deferred tax	—	—		—		9		—		—		—				9
Issuance of common stock, net of repurchases															Issuance of common stock, net of repurchases	—	—		30		—		—		—		(2)				28
Share-based compensation															Share-based compensation	—	—		66		—		—		—		—				66
Balance as of October 2, 2022															Balance as of October 2, 2022	197	2		9,129		39		1,281		(40)		(3,720)				6,731
Net loss															Net loss	—	—		—		—		(139)		—		—				(139)
Unrealized loss on cash flow hedges, net of deferred tax															Unrealized loss on cash flow hedges, net of deferred tax	—	—		—		(36)		—		—		—				(36)
Issuance of common stock, net of repurchases															Issuance of common stock, net of repurchases	1	—		—		—		—		—		(35)				(35)
Share-based compensation															Share-based compensation	—	—		78		—		—		—		—				78

Balance as of January 1, 2023															Balance as of January 1, 2023	198	$	2	$	9,207	$	3	$	1,142	(40)		$	(3,755)			$	6,599

See accompanying notes to condensed consolidated financial statements.

Table of Contents

ILLUMINA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In millions)


					Additional		Accumulated Other							Total																Additional	Accumulated Other					Total
		Common Stock			Paid-In		Comprehensive		Retained		Treasury Stock			Stockholders’												Common Stock				Paid-In	Comprehensive	Retained		Treasury Stock		Stockholders’
		Shares	Amount		Capital		Income		Earnings		Shares	Amount		Equity												Shares		Amount		Capital	Income (Loss)	Earnings		Shares	Amount	Equity

Balance as of January 2, 2022		197	$	2	$	8,938	$	17	$	5,485	(40)	$	(3,702)	$	10,740

Balance as of January 1, 2023																Balance as of January 1, 2023	198	$	2	$	9,207	$	3		$	1,142	(40)		$	(3,755)			$	6,599
Net income	Net income	—	—		—		—		86		—	—		86										Net income		—		—		—	—	3		—	—	3
Unrealized gain on cash flow hedges, net of deferred tax		—	—		—		1		—		—	—		1
Unrealized loss on cash flow hedges, net of deferred tax																Unrealized loss on cash flow hedges, net of deferred tax	—	—		—		(4)			—		—		—				(4)
Issuance of common stock, net of repurchases	Issuance of common stock, net of repurchases	—	—		33		—		—		—	(12)		21										Issuance of common stock, net of repurchases		—		—		37	—	—		—	(9)	28
Share-based compensation	Share-based compensation	—	—		79		—		—		—	—		79										Share-based compensation		—		—		67	—	—		—	—	67
Cumulative-effect adjustment from adoption of ASU 2020-06, net of deferred tax		—	—		(93)		—		61		—	—		(32)
Balance as of April 3, 2022		197	2		8,957		18		5,632		(40)	(3,714)		10,895

Balance as of April 2, 2023																Balance as of April 2, 2023	198	2		9,311		(1)			1,145		(40)		(3,764)				6,693
Net loss	Net loss	—	—		—		—		(535)		—	—		(535)										Net loss		—		—		—	—	(234)		—	—	(234)
Unrealized gain on cash flow hedges, net of deferred tax	Unrealized gain on cash flow hedges, net of deferred tax	—	—		—		12		—		—	—		12										Unrealized gain on cash flow hedges, net of deferred tax		—		—		—	13	—		—	—	13
Issuance of common stock, net of repurchases	Issuance of common stock, net of repurchases	—	—		—		—		—		—	(4)		(4)										Issuance of common stock, net of repurchases		—		—		—	—	—		—	(3)	(3)
Share-based compensation	Share-based compensation	—	—		76		—		—		—	—		76										Share-based compensation		—		—		77	—	—		—	—	77
Balance as of July 3, 2022		197	2		9,033		30		5,097		(40)	(3,718)		10,444
Reclassification of liability-classified awards																Reclassification of liability-classified awards	—	—		9		—			—		—		—				9

Balance as of July 2, 2023																Balance as of July 2, 2023	198	2		9,397		12			911		(40)		(3,767)				6,555
Net loss	Net loss	—	—		—		—		(3,816)		—	—		(3,816)										Net loss		—		—		—	—	(754)		—	—	(754)
Unrealized gain on cash flow hedges, net of deferred tax	Unrealized gain on cash flow hedges, net of deferred tax	—	—		—		9		—		—	—		9										Unrealized gain on cash flow hedges, net of deferred tax		—		—		—	9	—		—	—	9
Issuance of common stock, net of repurchases	Issuance of common stock, net of repurchases	—	—		30		—		—		—	(2)		28										Issuance of common stock, net of repurchases		—		—		30	—	—		—	(2)	28
Share-based compensation	Share-based compensation	—	—		66		—		—		—	—		66										Share-based compensation		—		—		60	—	—		—	—	60
Balance as of October 2, 2022		197	$	2	$	9,129	$	39	$	1,281	(40)	$	(3,720)	$	6,731

Balance as of October 1, 2023																Balance as of October 1, 2023	198	$	2	$	9,487	$	21		$	157	(40)		$	(3,769)			$	5,898

See accompanying notes to condensed consolidated financial statements.

Table of Contents

ILLUMINA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In millions)


		Nine Months Ended					Nine Months Ended
		October 2, 2022		October 3, 2021			October 1, 2023		October 2, 2022
Cash flows from operating activities:	Cash flows from operating activities:					Cash flows from operating activities:
Net (loss) income		$	(4,265)	$	650
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Net loss						Net loss	$	(986)	$	(4,265)
Adjustments to reconcile net loss to net cash provided by operating activities:						Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation expense	Depreciation expense	158		128		Depreciation expense	175		158
Amortization of intangible assets	Amortization of intangible assets	130		34		Amortization of intangible assets	148		130
Share-based compensation expense	Share-based compensation expense	266		656		Share-based compensation expense	286		266
Accretion of debt discount on convertible senior notes		—		26

Deferred income taxes	Deferred income taxes	(40)		(81)		Deferred income taxes	(42)		(40)
Goodwill impairment		3,914		—
Goodwill and intangible (IPR&D) impairment						Goodwill and intangible (IPR&D) impairment	821		3,914
Property and equipment and right-of-use asset impairment						Property and equipment and right-of-use asset impairment	56		—

Gain on previously held investment in GRAIL		—		(900)
Net losses (gains) on strategic investments		79		(46)
Net losses on strategic investments						Net losses on strategic investments	39		79

Loss (gain) on Helix contingent value right		8		(30)
(Gain) loss on Helix contingent value right						(Gain) loss on Helix contingent value right	(8)		8

Payment of accreted debt discount						Payment of accreted debt discount	(15)		—

Gain on derivative assets related to terminated acquisition		—		(26)
Change in fair value of contingent consideration liabilities	Change in fair value of contingent consideration liabilities	(230)		(7)		Change in fair value of contingent consideration liabilities	(82)		(230)
Unrealized loss on foreign exchange translation						Unrealized loss on foreign exchange translation	21		1
Other	Other	7		26		Other	9		6
Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Accounts receivable	Accounts receivable	13		(125)		Accounts receivable	(31)		13
Inventory	Inventory	(127)		(27)		Inventory	(47)		(127)
Prepaid expenses and other current assets	Prepaid expenses and other current assets	10		(34)		Prepaid expenses and other current assets	(3)		10
Operating lease right-of-use assets and liabilities, net	Operating lease right-of-use assets and liabilities, net	(10)		(9)		Operating lease right-of-use assets and liabilities, net	(13)		(10)
Other assets	Other assets	17		(35)		Other assets	6		17
Accounts payable	Accounts payable	(51)		(28)		Accounts payable	(50)		(51)
Accrued liabilities	Accrued liabilities	388		81		Accrued liabilities	(25)		388

Other long-term liabilities	Other long-term liabilities	(22)		10		Other long-term liabilities	(5)		(22)
Net cash provided by operating activities	Net cash provided by operating activities	245		263		Net cash provided by operating activities	254		245
Cash flows from investing activities:	Cash flows from investing activities:					Cash flows from investing activities:
Maturities of available-for-sale securities		—		331
Purchases of available-for-sale securities		—		(77)
Sales of available-for-sale securities		—		1,031

Cash received for derivative assets related to terminated acquisition		—		52

Purchases of property and equipment	Purchases of property and equipment	(198)		(138)		Purchases of property and equipment	(144)		(198)

Purchases of strategic investments	Purchases of strategic investments	(26)		(44)		Purchases of strategic investments	(19)		(26)
Sales of strategic investments	Sales of strategic investments	—		220		Sales of strategic investments	18		—
Net cash paid for acquisitions	Net cash paid for acquisitions	(85)		(2,444)		Net cash paid for acquisitions	—		(85)
Cash paid for intangible asset	Cash paid for intangible asset	(180)		—		Cash paid for intangible asset	(1)		(180)
Net cash used in investing activities	Net cash used in investing activities	(489)		(1,069)		Net cash used in investing activities	(146)		(489)
Cash flows from financing activities:	Cash flows from financing activities:					Cash flows from financing activities:

Debt issuance costs paid for credit facility						Debt issuance costs paid for credit facility	(1)		—

Net proceeds from issuance of debt		—		988
Payments on convertible senior notes		—		(517)

Payments on financing obligations						Payments on financing obligations	(1,235)		—

Taxes paid related to net share settlement of equity awards	Taxes paid related to net share settlement of equity awards	(19)		(452)		Taxes paid related to net share settlement of equity awards	(14)		(19)

Proceeds from issuance of common stock	Proceeds from issuance of common stock	63		59		Proceeds from issuance of common stock	67		63

Net cash provided by financing activities		44		78
Net cash (used in) provided by financing activities						Net cash (used in) provided by financing activities	(1,183)		44
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(32)		(2)		Effect of exchange rate changes on cash and cash equivalents	(9)		(32)
Net decrease in cash and cash equivalents	Net decrease in cash and cash equivalents	(232)		(730)		Net decrease in cash and cash equivalents	(1,084)		(232)
Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	1,232		1,810		Cash and cash equivalents at beginning of period	2,011		1,232
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	$	1,000	$	1,080	Cash and cash equivalents at end of period	$	927	$	1,000

See accompanying notes to condensed consolidated financial statements.

Table of Contents

ILLUMINA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Unless the context requires otherwise, references in this report to “Illumina,” the “Company,” “we,” “us,~~” the “Company,~~” and “our” refer to Illumina, Inc. and its consolidated subsidiaries.


1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Business Overview

We are a provider of sequencing- and array-based solutions, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. Our customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

On August 18, 2021, we acquired GRAIL, a healthcare company focused on early detection of multiple cancers. ~~GRAIL’s Galleri blood test detects various types of cancers before they are symptomatic.~~ The acquisition is subject to ongoing legal proceedings and, currently, GRAIL ~~is currently being~~must be held and operated ~~as a separate company, with oversight provided~~separately and independently from Illumina pursuant to the transitional measures ordered by ~~an appointed, independent monitoring trustee.~~the European Commission in the EC Divestment Decision, following the prohibition of our acquisition of GRAIL on September 6, 2022. Refer to note “7. Legal Proceedings” for additional details. We have included the financial results of GRAIL in our condensed consolidated financial statements from the date of acquisition. We finalized the allocation of the purchase price for the GRAIL acquisition in August 2022. See note “~~6. Supplemental Balance Sheet~~ ~~Details.” In addition,~~ GRAIL is a separate reportable segment. ~~Refer~~

With respect to ~~note “9. Segment Information~~”GRAIL, we have retained advisors and are preparing for ~~additional details.~~sale and capital markets transaction options in accordance with the European Commission’s divestiture order. In parallel, ongoing appeals preserve flexibility for any divestiture of GRAIL and future transactions.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Interim financial results are not necessarily indicative of results anticipated for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Annual Report on Form 10-K for the fiscal year ended January ~~2, 2022,~~1, 2023, from which the prior year balance sheet information herein was derived. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expense, and related disclosure of contingent assets and liabilities. Though the ~~impact of the~~ COVID-19 pandemic, ~~to our business~~the armed conflict between Russia and ~~operating results presents~~Ukraine, and macroeconomic factors such as inflation, exchange rates and concerns about an economic downturn present additional uncertainty, we continue to use the best information available to form our critical accounting estimates. Actual results could differ from those estimates.

The unaudited condensed consolidated financial statements include our accounts, our wholly-owned subsidiaries, and majority-owned or controlled companies. All intercompany transactions and balances have been eliminated in consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. In management’s opinion, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Fiscal Year

Our fiscal year is the 52 or 53 weeks ending the Sunday closest to December 31, with quarters of 13 or 14 weeks ending the Sunday closest to March 31, June 30, September 30, and December 31. References to Q3 ~~2022~~2023 and Q3 ~~2021~~2022 refer to the three months ended October ~~2, 2022~~1, 2023 and October ~~3, 2021,~~2, 2022, respectively, which were both 13 weeks, and references to year-to-date (YTD) ~~2022~~2023 and ~~2021~~2022 refer to the nine months ended October ~~2, 2022~~1, 2023 and October ~~3, 2021,~~2, 2022, respectively, which were both 39 weeks.

Table of Contents

Significant Accounting Policies

During YTD ~~2022,~~2023, there were no changes to our significant accounting policies as described in our Annual Report on Form 10-K for the fiscal year ended January ~~2, 2022, except as described in Recently Adopted Accounting Pronouncements below.~~

~~Recently Adopted Accounting Pronouncements~~

~~In August 2020,~~1, 2023, with the ~~FASB issued ASU 2020-06,~~ ~~Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40).~~ The new standard reduces the number of accounting models for convertible debt instruments, amends the accounting for certain contracts in an entity’s own equity, and modifies how certain convertible instruments and contracts that may be settled in cash or shares impact the calculation of diluted earnings per share. Specifically, the guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments and requires the useexception of the ~~if-converted~~following for income taxes:

Historically, we calculated the provision/(benefit) for income taxes for interim periods utilizing an estimated annual effective tax rate applied to the income/(loss) for the reporting period, except in Q2 2023 when a year-to-date effective tax rate method ~~to calculate diluted earnings per share.~~ was utilized.We ~~adopted~~determined the ~~standard on its~~estimated annual effective ~~date~~tax rate method would provide a more reliable estimate of the provision for income taxes for Q3 2023 and YTD 2023 since minor changes in the ~~first quarter of 2022 using a modified retrospective approach by recognizing a cumulative-effect adjustment to retained earnings on January 3, 2022. We did~~estimated income/(loss) before income taxes would not ~~restate prior periods. As a~~ result ofin significant changes in the ~~adoption, we increased our convertible senior notes and retained earnings, on January 3, 2022, by $43 million and $61 million, respectively, and decreased our deferred~~estimated annual effective tax liabilities, included in other long-term liabilities on the condensed consolidated balance sheets, and additional paid-in capital by $11 million and $93 million, respectively. Interest expense recognized in future periods will be reduced as a result of accounting for our convertible senior notes as a single liability measured at amortized cost. See note “~~4. Debt” for additional details on the adoption of ASU 2020-06.~~rate.

~~Earnings (Loss)~~Loss per Share

Basic ~~earnings (loss)~~loss per share is computed based on the weighted average number of common shares outstanding during the period. Diluted ~~earnings (loss)~~loss per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. In loss periods, basic and diluted loss per share are identical since the effect of potentially dilutive common shares is antidilutive and therefore excluded.

Potentially dilutive common shares consist of shares issuable under convertible senior notes and equity awards. ~~On January 3, 2022, we adopted ASU 2020-06. As a result, beginning in Q1 2022, we~~We utilize the if-converted method to calculate the impact of convertible senior notes on diluted ~~earnings (loss)~~loss per share. Prior to the adoption of ASU 2020-06, we applied the treasury stock method when calculating the potential dilutive effect, if any, of convertible senior notes which we intended to settle or have settled in cash the principal outstanding. Under the treasury stock method, convertible senior notes would have a dilutive impact when the average market price of our common stock exceeded the applicable conversion price of the respective notes. Potentially dilutive common shares from equity awards are determined using the average share price for each period under the treasury stock method. In addition, proceeds from exercise of equity awards and the average amount of unrecognized compensation expense for equity awards are assumed to be used to repurchase shares. ~~In loss periods, basic loss per share and diluted loss per share are identical since the effect of dilutive potential common shares is anti-dilutive and therefore excluded.~~

~~Table of Contents~~

The following table presents the ~~calculation of~~ weighted average shares used to calculate basic and diluted ~~earnings (loss)~~loss per share:

In millions Q3 2022 Q3 2021 YTD 2022 YTD 2021
Weighted average shares outstanding 157 152 157 148
Effect of potentially dilutive common shares from:
Equity awards — 1 — 1
Weighted average shares used in calculating diluted earnings (loss) per share 157 153 157 149
Anti-dilutive shares:
Convertible senior notes 2 — 2 —
Equity awards 2 — 2 —
Potentially dilutive shares excluded from calculation due to anti-dilutive effect 4 — 4 —



In millions	Q3 2023	Q3 2022	YTD 2023	YTD 2022




Weighted average shares used in calculating basic loss per share	158	157	158	157




Weighted average shares used in calculating diluted loss per share	158	157	158	157

Antidilutive shares:
Convertible senior notes	1	2	1	2
Equity awards	3	2	3	2
Potentially dilutive shares excluded from calculation due to antidilutive effect	4	4	4	4


2. REVENUE

Our revenue is generated primarily from the sale of products and services. Product revenue primarily consists of sales of instruments and consumables used in genetic analysis. Service and other revenue primarily consists of revenue generated from genotyping and sequencing services, instrument service contracts, development and licensing agreements, and cancer detection testing services related to the GRAIL business.

Revenue by Source


		Q3 2022						Q3 2021							Q3 2023						Q3 2022
In millions	In millions	Sequencing		Microarray		Total		Sequencing		Microarray		Total		In millions	Sequencing		Microarray		Total		Sequencing		Microarray		Total
Consumables	Consumables	$	720	$	76	$	796	$	723	$	71	$	794	Consumables	$	689	$	71	$	760	$	720	$	76	$	796
Instruments	Instruments	162		5		167		180		4		184		Instruments	178		3		181		162		5		167

Total product revenue	Total product revenue	882		81		963		903		75		978		Total product revenue	867		74		941		882		81		963
Service and other revenue	Service and other revenue	133		19		152		112		18		130		Service and other revenue	162		16		178		133		19		152
Total revenue	Total revenue	$	1,015	$	100	$	1,115	$	1,015	$	93	$	1,108	Total revenue	$	1,029	$	90	$	1,119	$	1,015	$	100	$	1,115

YTD 2022 YTD 2021
In millions Sequencing Microarray Total Sequencing Microarray Total
Consumables $ 2,237 $ 225 $ 2,462 $ 2,123 $ 224 $ 2,347
Instruments 563 14 577 544 12 556
Total product revenue 2,800 239 3,039 2,667 236 2,903
Service and other revenue 390 72 462 348 76 424
Total revenue $ 3,190 $ 311 $ 3,501 $ 3,015 $ 312 $ 3,327

Table of Contents



	YTD 2023						YTD 2022
In millions	Sequencing		Microarray		Total		Sequencing		Microarray		Total
Consumables	$	2,108	$	219	$	2,327	$	2,237	$	225	$	2,462
Instruments	524		13		537		563		14		577
Total product revenue	2,632		232		2,864		2,800		239		3,039
Service and other revenue	456		62		518		390		72		462
Total revenue	$	3,088	$	294	$	3,382	$	3,190	$	311	$	3,501

Revenue by Geographic Area


Based on region of destination (in millions)	Based on region of destination (in millions)	Q3 2022		Q3 2021		YTD 2022		YTD 2021		Based on region of destination (in millions)	Q3 2023		Q3 2022(1)		YTD 2023		YTD 2022(1)
Americas	Americas	$	597	$	583	$	1,885	$	1,733	Americas	$	663	$	597	$	1,920	$	1,885
Europe, Middle East, and Africa		290		313		914		938
Europe										Europe	260		259		825		819
Greater China~~(1)~~(2)	Greater China~~(1)~~(2)	133		122		378		382		Greater China~~(1)~~(2)	98		133		302		378
Asia-Pacific		95		90		324		274
Asia-Pacific, Middle East, and Africa(3)										Asia-Pacific, Middle East, and Africa(3)	98		126		335		419
Total revenue	Total revenue	$	1,115	$	1,108	$	3,501	$	3,327	Total revenue	$	1,119	$	1,115	$	3,382	$	3,501

_____________

(1)We implemented a new global commercial structure in Q1 2023 to improve operating efficiencies and better align with local markets. We integrated Asia-Pacific and Japan with emerging markets across the Middle East, Africa, Turkey, and Commonwealth of Independent States (CIS). Beginning in Q1 2023, and going forward, we will report regional results for the following regions: Americas, Europe, Greater China, and Asia-Pacific, Middle East and Africa (AMEA). Prior period amounts have been reclassified to conform to this new presentation.

(2)Region includes revenue from China, Taiwan, and Hong Kong.

~~Table of Contents~~(3)

Region includes revenue from Russia and Turkey.

Performance Obligations

We regularly enter into contracts with multiple performance obligations. These contracts are believed to be firm as of the balance sheet date. However, we may allow customers to make product substitutions as we launch new products. The timing of shipments depends on several factors, including agreed upon shipping schedules, which may span multiple quarters. Most performance obligations are generally satisfied within a short time frame, approximately three to six months, after the contract execution date. As of October ~~2, 2022,~~1, 2023, the aggregate amount of the transaction price allocated to remaining performance obligations was ~~$974~~$743 million, of which approximately ~~88%~~83% is expected to be converted to revenue in the next twelve months, approximately 6%10% in the following twelve months, and the remainder thereafter.

Contract Assets and Liabilities

Contract assets, which consist of revenue recognized and performance obligations satisfied or partially satisfied in advance of customer billing, were ~~$17~~$19 million and ~~$16~~$17 million as of October ~~2, 2022~~1, 2023 and January ~~2, 2022,~~1, 2023, respectively, and were recorded in prepaid expenses and other current assets.

Contract liabilities, which consist of deferred revenue and customer deposits, as of October ~~2, 2022~~1, 2023 and January ~~2, 2022~~1, 2023 were ~~$288~~$315 million and ~~$297~~$308 million, respectively, of which the short-term portions of ~~$225~~$242 million and ~~$234~~$245 million, respectively, were recorded in accrued liabilities and the remaining long-term portions were recorded in other long-term liabilities. Revenue recorded in Q3 ~~2022~~2023 and YTD ~~2022~~ 2023included ~~$41~~$43 million and $206 million, respectively, of previously deferred revenue that was included in contract liabilities as of January ~~2, 2022.~~1, 2023.


3. INVESTMENTS AND FAIR VALUE MEASUREMENTS

Strategic Investments

Marketable Equity Securities

Our short-term investments consist of marketable equity securities. As of October ~~2, 2022~~1, 2023 and January ~~2, 2022,~~1, 2023, the fair value of our marketable equity securities totaled ~~$41~~$6 million and ~~$107~~$26 million, respectively.

~~Net gains (losses)~~

Table of Contents

Gains and losses recognized in other ~~(expense) income,~~expense, net on our marketable equity securities were as follows:


In millions	In millions	Q3 2022		Q3 2021		YTD 2022		YTD 2021		In millions	Q3 2023		Q3 2022		YTD 2023		YTD 2022
Net gains (losses) recognized during the period on marketable equity securities	Net gains (losses) recognized during the period on marketable equity securities	$	3	$	45	$	(66)	$	(23)	Net gains (losses) recognized during the period on marketable equity securities	$	—	$	3	$	(2)	$	(66)
Less: Net losses recognized during the period on marketable equity securities sold during the period	Less: Net losses recognized during the period on marketable equity securities sold during the period	—		—		—		(7)		Less: Net losses recognized during the period on marketable equity securities sold during the period	—		—		(2)		—
Net unrealized gains (losses) recognized during the period on marketable equity securities still held at the reporting date	Net unrealized gains (losses) recognized during the period on marketable equity securities still held at the reporting date	$	3	$	45	$	(66)	$	(16)	Net unrealized gains (losses) recognized during the period on marketable equity securities still held at the reporting date	$	—	$	3	$	—	$	(66)

Non-Marketable Equity Securities

As of October ~~2, 2022~~1, 2023 and January ~~2, 2022,~~1, 2023, the aggregate carrying amounts of our non-marketable equity securities without readily determinable fair values, included in other assets, were ~~$42 million and $40 million, respectively.~~$28 million.

Revenue recognized from transactions with our strategic investees was $2 million and $68 million for Q3 2023 and YTD 2023, respectively, and $27 million and $83 million for Q3 2022 and YTD 2022, ~~respectively, and $14 million and $47 million for Q3 2021 and YTD 2021~~, respectively.

Venture Funds

We invest in two venture capital investment funds (the Funds) with capital commitments of $100 million, callable through April 2026, and up to $150 million, callable through July 2029, respectively, of which ~~$11~~$5 million and up to ~~$101~~$74 million, respectively, remained callable as of October ~~2, 2022.~~1, 2023. Our investments in the Funds are accounted for as equity-method investments. The aggregate carrying amounts of the Funds, included in other assets, were ~~$184~~$165 million and ~~$173~~$183 million as of October ~~2, 2022~~1, 2023 and January ~~2, 2022,~~1, 2023, respectively. We

~~Table~~ recorded unrealized losses of ~~Contents~~

~~recorded~~$19 million and $33 million in Q3 2023 and YTD 2023, respectively, and unrealized losses of $5 million and $11 million in Q3 2022 and YTD 2022, respectively, ~~and unrealized gains of $23 million in Q3 2021 and $54 million in YTD 2021,~~ in other ~~(expense) income,~~expense, net.

Helix Contingent Value Right

In conjunction with the deconsolidation of Helix Holdings I, LLC (Helix) in April 2019, we received a contingent value right with a 7-year term that entitles us to consideration dependent upon the outcome of Helix’s future financing and/or liquidity events. Changes in the fair value of ~~the~~our contingent value right resulted in unrealized gains of $5 million

Table of Contents

and $8 million in Q3 2023 and YTD 2023, respectively, and unrealized losses of $5 million and $8 million in Q3 2022 and YTD 2022, respectively, ~~and unrealized gains of $12 million and $30 million in Q3 2021 and YTD 2021, respectively,~~ which were included in other ~~(expense) income,~~expense, net.

~~Derivative Assets Related to Terminated Acquisition~~

~~Pursuant to the Agreement and Plan of Merger (the PacBio~~ ~~Merger Agreement) to acquire Pacific Biosciences of California, Inc. (PacBio) entered into in November 2018 and amended in September 2019 (Amendment No. 1 to the PacBio Merger Agreement) and the subsequent agreement to terminate the PacBio Merger Agreement (the~~ ~~Termination Agreement~~) entered into in January 2020, we made cash payments to PacBio of $18 million in Q4 2019 and $34 million in Q1 2020, respectively, collectively referred to as the Continuation Advances. Up to the $52 million of Continuation Advances was repayable, without interest, if, within two years of March 31, 2020, PacBio entered into a Change of Control Transaction or raised at least $100 million in equity or debt financing in a single transaction (with the amount repayable dependent on the amount raised by PacBio). In February 2021, PacBio entered into an investment agreement with SB Northstar LP for the issuance and sale of $900 million in aggregate principal amount of PacBio’s convertible notes. Pursuant to the PacBio Merger Agreement, PacBio repaid to us the $52 million of Continuation Advances and we recorded a gain of $26 million in Q1 2021, which was included in other (expense) income, net.

Fair Value Measurements

The following table presents the hierarchy for assets and liabilities measured at fair value on a recurring basis:


		October 2, 2022								January 2, 2022									October 1, 2023								January 1, 2023
In millions	In millions	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total		In millions	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:	Assets:																	Assets:
Money market funds (cash equivalents)	Money market funds (cash equivalents)	$	551	$	—	$	—	$	551	$	688	$	—	$	—	$	688	Money market funds (cash equivalents)	$	646	$	—	$	—	$	646	$	1,642	$	—	$	—	$	1,642

Marketable equity securities	Marketable equity securities	41		—		—		41		107		—		—		107		Marketable equity securities	6		—		—		6		26		—		—		26
Helix contingent value right	Helix contingent value right	—		—		57		57		—		—		65		65		Helix contingent value right	—		—		66		66		—		—		58		58

Deferred compensation plan assets	Deferred compensation plan assets	—		49		—		49		—		60		—		60		Deferred compensation plan assets	—		57		—		57		—		52		—		52
Total assets measured at fair value	Total assets measured at fair value	$	592	$	49	$	57	$	698	$	795	$	60	$	65	$	920	Total assets measured at fair value	$	652	$	57	$	66	$	775	$	1,668	$	52	$	58	$	1,778
Liabilities:	Liabilities:																	Liabilities:
Contingent consideration liabilities	Contingent consideration liabilities	$	—	$	—	$	387	$	387	$	—	$	—	$	615	$	615	Contingent consideration liabilities	$	—	$	—	$	330	$	330	$	—	$	—	$	412	$	412
Deferred compensation plan liability	Deferred compensation plan liability	—		46		—		46		—		56		—		56		Deferred compensation plan liability	—		54		—		54		—		51		—		51
Total liabilities measured at fair value	Total liabilities measured at fair value	$	—	$	46	$	387	$	433	$	—	$	56	$	615	$	671	Total liabilities measured at fair value	$	—	$	54	$	330	$	384	$	—	$	51	$	412	$	463

Table of Contents

Our marketable equity securities are measured at fair value based on quoted trade prices in active markets. Our deferred compensation plan assets consist primarily of investments in life insurance contracts carried at cash surrender value, which reflects the net asset value of the underlying publicly traded mutual funds. We perform control procedures to corroborate the fair value of our holdings, including comparing valuations obtained from our investment service provider to valuations reported by our asset custodians, validating pricing sources and models, and reviewing key model inputs, if necessary.

We elected the fair value option to measure the contingent value right received from Helix. The fair value of such contingent value right, included in other assets, is derived using a Monte Carlo simulation. Estimates and assumptions used in the Monte Carlo simulation include probabilities related to the timing and outcome of future financing and/or liquidity events, assumptions regarding collectibility and volatility, and an estimated equity value of Helix. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value.

We reassess the fair value of contingent consideration related to acquisitions on a quarterly basis. Changes in the fair value of contingent consideration subsequent to the acquisition date are recognized in selling, general and administrative expense. The contingent value rights issued as part of the GRAIL acquisition entitle the holders to receive future cash payments on a quarterly basis (Covered Revenue Payments) representing a pro rata portion of certain GRAIL-related revenues (Covered Revenues) each year for a 12-year period. As defined in the Contingent Value Rights Agreement, this will reflect a 2.5% payment right to the first $1 billion of revenue each year for 12 years. Revenue above $1 billion each year will be subject to a 9% contingent payment right during this same period. Covered Revenues for Q4 2022, Q1 2023, and Q2 2023 were $65 million in aggregate and Covered Revenues for Q4 2021, Q1 2022, and Q2 2022 were $32 million in aggregate, driven primarily by sales of GRAIL’s Galleri test. ~~Corresponding~~ Covered Revenue Payments relating to such periods were approximately $609,000 and $297,000 in YTD 2023 and YTD 2022, ~~were approximately $297,000; however, pursuant~~respectively. Pursuant to the Contingent Value Rights Agreement, a portion of the Covered Revenue Payments in YTD 2022 were applied to reimburse us for certain expenses. We use a Monte Carlo simulation to estimate the fair value of contingent consideration related to the GRAIL acquisition. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues for GRAIL, a revenue risk premium, a revenue volatility estimate, an operational leverage ratio and a counterparty credit spread. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Changes in the fair value of contingent consideration subsequent to the acquisition date are recognized in selling, general and administrative expense in our condensed consolidated statements of operations. The fair value of our contingent consideration liability related to ~~the~~ GRAIL ~~acquisition~~ was ~~$387~~$330 million and ~~$615~~$412 million as of October ~~2, 2022~~1, 2023 and January ~~2, 2022,~~1, 2023, respectively, of which ~~$386~~$329 million and ~~$614~~$411 million, respectively, was included in other long-term liabilities, with the remaining balances included in accrued liabilities.

Changes in the estimated fair value of our contingent consideration liabilities during YTD ~~2022~~2023 were as follows:


In millions
Balance as of January ~~2, 2022~~1, 2023	$	~~615~~412

~~Acquisition~~	2

Change in estimated fair value	~~(230)~~(82)

Balance as of October ~~2, 2022~~1, 2023	$	~~387~~330


4. DEBT

Summary of Term Debt Obligations


In millions	In millions	October 2, 2022		January 2, 2022		In millions	October 1, 2023		January 1, 2023

Principal amount of 2031 Term Notes outstanding	Principal amount of 2031 Term Notes outstanding	$	500	$	500	Principal amount of 2031 Term Notes outstanding	$	500	$	500
Principal amount of 2027 Term Notes outstanding						Principal amount of 2027 Term Notes outstanding	500		500
Principal amount of 2025 Term Notes outstanding						Principal amount of 2025 Term Notes outstanding	500		500
Principal amount of 2023 Term Notes outstanding	Principal amount of 2023 Term Notes outstanding	500		500		Principal amount of 2023 Term Notes outstanding	—		500
Unamortized discounts and debt issuance costs	Unamortized discounts and debt issuance costs	(6)		(7)		Unamortized discounts and debt issuance costs	(11)		(13)
Net carrying amount of term notes	Net carrying amount of term notes	994		993		Net carrying amount of term notes	1,489		1,987
Less: current portion	Less: current portion	(499)		—		Less: current portion	—		(500)
Term notes, non-current	Term notes, non-current	$	495	$	993	Term notes, non-current	$	1,489	$	1,487
Fair value of term notes outstanding (Level 2)	Fair value of term notes outstanding (Level 2)	$	877	$	996	Fair value of term notes outstanding (Level 2)	$	1,375	$	1,913

Table of Contents

Interest expense recognized on our term notes, which included amortization of debt discounts and issuance costs, was $18 million and $55 million in Q3 2023 and YTD 2023, respectively, and $4 million and $13 million in Q3 2022 and YTD 2022, respectively.

0.550% Term Notes due 2023 (2023 Term Notes) and 2.550% Term Notes due 2031 (2031 Term Notes)

OnIn March ~~23,~~ 2021, we issued $500 million aggregate principal amount of ~~term notes due~~ 2023 ~~(2023~~ Term ~~Notes)~~Notes and $500 million aggregate principal amount of ~~term notes due~~ 2031 ~~(2031~~Term Notes. The 2023 Term Notes ~~together the Term Notes). We received net proceeds from the issuance of $992 million, after deducting discounts~~matured and ~~debt issuance costs.~~were repaid in cash on March 23, 2023.

The ~~2023 and~~ 2031 Term Notes, which mature on March 23, 2031, accrue interest at a rate of ~~0.550% and~~ 2.550% per annum, ~~respectively,~~ payable ~~semi-annually. Interest is payable~~semi-annually on March 23 and September 23 of each ~~year, beginning on September 23, 2021. The 2023 Term Notes mature on March 23, 2023, and the 2031 Term Notes mature on March 23, 2031.~~

year. We may redeem for cash all or any portion of the 2031 Term Notes, at our option, at any time prior to maturity. ~~The 2023 Term Notes and, prior~~Prior to December 23, 2030, the 2031 Term Notes are redeemable at make-whole premium redemption prices as defined in the applicable forms of note. After December 23, 2030, the ~~2031 Term Notes~~notes are redeemable at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus any accrued and unpaid interest up to, but excluding, the redemption date.

~~Interest expense recognized on the~~5.800% Term Notes ~~which included amortization of debt discounts~~due 2025 (2025 Term Notes) and ~~issuance costs, was $4 million and $13 million in Q3 2022 and YTD 2022, respectively, and $4 million and $9 million in Q3 2021 and YTD 2021, respectively.~~

~~0% Convertible Senior~~5.750% Term Notes due ~~2023 (2023 Convertible~~2027 (2027 Term Notes)

In millions October 2,
2022 January 2,
2022
Principal amount outstanding $ 750 $ 750
Unamortized debt discount and issuance costs (3) (48)
Net carrying amount of liability component $ 747 $ 702
Less: current portion (747) —
Convertible senior notes, non-current $ — $ 702
Carrying value of equity component, net of debt issuance costs $ — $ 126
Fair value of convertible senior notes outstanding (Level 2) $ 721 $ 854

In ~~August 2018,~~December 2022, we issued ~~$750~~$500 million aggregate principal amount of ~~convertible senior notes due 2023 (2023 Convertible Notes). The 2023 Convertible~~2025 Term Notes ~~carry no coupon interest~~ and ~~mature on August 15, 2023.~~

The 2023 Convertible Notes will be convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election, based on an initial conversion rate, subject to adjustment, of 2.1845 shares of common stock per $1,000$500 million aggregate principal amount of notes (which represents an initial conversion price of approximately $457.77 per share of common stock), only in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending2027 Term Notes. The 2025 Term Notes, which mature on September 30, 2018 (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price in effect on each applicable trading day; (2) during the five business day period after any 10 consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of 2023 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of our common stockDecember 12, 2025, and the ~~conversion~~2027 Term Notes, which mature on December 13, 2027, accrue interest at a rate of 5.800% and 5.750% per annum, respectively, payable semi-annually. Interest for the 2025 Term Notes is payable on June 12 and December 12 of each ~~such trading day; (3) if we call any or all~~year, beginning on June 12, 2023. Interest for the 2027 Term Notes is payable on June 13 and December 13 of ~~the notes for redemption, at any time prior to the close of business~~each year, beginning on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events described in the indenture. Regardless of the foregoing circumstances, the holders may convert their notes on or after May 15, 2023 until August 11,June 13, 2023. ~~The 2023 Convertible Notes were not convertible as of October 2, 2022.~~

~~Table of Contents~~

We may redeem for cash all or any portion of the ~~2023 Convertible~~2025 or 2027 Term Notes, at our option, ~~on or~~at any time prior to maturity. Prior to November 12, 2025 for the 2025 Term Notes and prior to November 13, 2027 for the 2027 Term Notes, the notes are redeemable at make-whole premium redemption prices as defined in the applicable forms of note. After November 12, 2025 for the 2025 Term Notes and after ~~August 20, 2021 if~~November 13, 2027 for the ~~last reported sale price of our common stock has been at least 130% of~~2027 Term Notes, the conversion price then in effect (currently $595.10) for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemptionnotes are redeemable at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus any accrued and unpaid ~~special~~ interest up to, but excluding, the redemption date.

At the time of issuance, the embedded conversion feature of the 2023 Convertible Notes was required to be bifurcated from the notes and accounted for as an equity instrument classified within stockholders’ equity. As a result, we recognized $126 million in additional paid-in capital in 2018, which was recorded as a debt discount and subsequently amortized to interest expense at an estimated effective rate, assuming no conversion option, of 3.7%. As of January 3, 2022, we adopted ASU 2020-06, which removed the requirement to separate the embedded conversion feature from the notes and requires the notes to be accounted for as a single liability measured at amortized cost. Accordingly, we reclassified the unamortized debt discount from additional paid-in capital to convertible senior notes in the condensed consolidated balance sheets on January 3, 2022. This resulted in an increase to our convertible senior notes and retained earnings of $43 million and $61 million, respectively, and a decrease to our deferred tax liabilities, included in other long-term liabilities, and additional paid-in capital of $11 million and $93 million, respectively.

Interest expense recognized on the 2023 Convertible Notes, which included amortization of debt issuance costs, was $1 million and $2 million in Q3 2022 and YTD 2022, respectively. Interest expense recognized on the 2023 Convertible Notes in Q3 2021 and YTD 2021 was $7 million and $21 million, respectively, which included amortization of the original debt discount and debt issuance costs.

~~0.5%~~0% Convertible Senior Notes due ~~2021 (2021~~2023 (2023 Convertible Notes)

In ~~June 2014,~~August 2018, we issued ~~$517~~$750 million aggregate principal amount of 2023 Convertible Notes. The notes were convertible ~~senior notes due 2021 (2021 Convertible Notes).~~into cash, shares of common stock, or a combination of cash and shares of common stock, at our election, based on conversion rates as defined in the indenture. The ~~2021~~2023 Convertible Notes matured on ~~June~~August 15, ~~2021, by~~2023, at which time the principal ~~had been converted and~~ was repaid in cash. ~~The excess of the conversion value over the principal amount was paid in 0.7 million~~We did not issue any shares of common stock ~~and we recorded a loss on extinguishment of debt of $1 million~~ in ~~Q2 2021. Interest expense recognized on~~connection with the ~~2021~~2023 Convertible Notes, which included amortization of debt discount and issuance costs, was $7 million in YTD 2021, respectively. Our adoption of ASU 2020-06 on January 3, 2022 did not impact the accounting for the 2021 Convertible Notes since they were converted and repaid prior to the date of adoption.Notes.

Credit Agreement

On ~~March 8, 2021,~~January 4, 2023, we entered into a new credit agreement (the Credit Agreement), which provides us with a $750 million senior unsecured ~~five-year~~five-year revolving credit facility, including a $40 million sublimit for swingline borrowings and a $50 million sublimit for letters of credit (the Credit Facility). The proceeds of the loans under the Credit Facility may be used to finance working capital needs and for general corporate purposes. The credit agreement dated as of March 8, 2021 and the commitments thereunder were terminated as of January 4, 2023.

The Credit Facility matures, and all amounts outstanding thereunder become due and payable in full, on January 4, 2028, subject to two one-year extensions at our option, the consent of the extending lenders and certain other conditions. We may prepay amounts borrowed and terminate commitments under the Credit Facility at any time without premium or penalty. As of October 1, 2023, there were no borrowings or letters of credit outstanding under the Credit Facility and we were in compliance with all financial and operating covenants.

Any loans under the Credit Facility will have a variable interest rate based on either the ~~eurocurrency~~term secured overnight financing rate or the alternate base rate, plus an applicable ~~spread~~rate that varies with the Company’s debt ~~rating.~~rating and, in the case of loans bearing interest based on the term secured overnight financing rate, a credit spread adjustment equal to 0.10% per annum. The Credit Agreement includes an option for us to elect to increase the commitments

Table of Contents

under the Credit Facility or to enter into one or more tranches of term loans in the aggregate principal amount of up to $250 million, subject to the consent of the lenders providing the additional commitments or term loans, as applicable, and certain other conditions.

The Credit Agreement contains financial and operating covenants. Pursuant to the Credit Agreement, we are required to maintain a ratio of total debt to annual earnings before interest, taxes, depreciation and amortization (EBITDA), calculated based on the four consecutive fiscal quarters ending with the most recent fiscal quarter, of not greater than 3.50 to 1.00 as of the end of each fiscal quarter. Upon the consummation of any Qualified Acquisition (as defined in the Credit Agreement) and us providing notice to the Administrative Agent, the ratio increases to 4.00 to 1.00 for the fiscal quarter in which the acquisition is consummated and the three consecutive fiscal quarters thereafter. The operating covenants include, among other things, limitations on (i) the incurrence of indebtedness by our subsidiaries, (ii) liens on our and our subsidiaries assets, and (iii) certain fundamental changes and the disposition of assets by us and our subsidiaries. The Credit Agreement contains other customary covenants, representations and warranties, and events of default.

~~Table of Contents~~

The Credit Facility matures, and all amounts outstanding thereunder become due and payable in full, on March 8, 2026, subject to two one-year extensions at our option, the consent of the extending lenders and certain other conditions. We may prepay amounts borrowed and terminate commitments under the Credit Facility at any time without premium or penalty.

~~As of October 2, 2022, there were no borrowings outstanding under the Credit Facility, and we were in compliance with all financial and operating covenants.~~


5. STOCKHOLDERS’ EQUITY

In Q2 2023, the Company’s stockholders approved an amended and restated version of the Company’s 2015 Stock Incentive Plan (2015 Stock Plan) and increased the maximum number of shares authorized for issuance by 8.0 million shares. As of October ~~2, 2022,~~1, 2023, approximately ~~1.8~~8.2 million shares remained available for future grants under the 2015 Stock ~~and Incentive Compensation~~ Plan.

Restricted Stock

Restricted stock activity was as follows:


		Restricted Stock Units (RSU)	Performance Stock Units (PSU)(1)		Weighted-Average Grant Date Fair Value per Share								Restricted Stock Units (RSU)		Performance Stock Units (PSU)(1)	Weighted-Average Grant Date Fair Value per Share
Units in thousands	Units in thousands			RSU			PSU		Units in thousands					RSU		PSU
Outstanding at January 2, 2022		1,130		328			$	345.66			$	466.42
Outstanding at January 1, 2023											Outstanding at January 1, 2023		1,611		74	$	311.23	$	446.74
Awarded	Awarded	1,175	(111)		$	316.48			$	476.80	Awarded		2,000		62	$	197.09	$	245.08
Vested	Vested	(109)	—		$	386.20			$	—	Vested		(118)		—	$	296.25	$	—
Cancelled	Cancelled	(149)	(34)		$	343.26			$	423.89	Cancelled		(411)		(96)	$	255.53	$	300.09
Outstanding at October 2, 2022		2,047	183		$	326.88			$	468.11
Outstanding at October 1, 2023											Outstanding at October 1, 2023		3,082		40	$	245.37	$	198.25

_____________

(1)The number of units reflect the estimated number of shares to be issued at the end of the performance period. For market-based PSU, the number of units reflect the estimated number of shares to be issued based on performance as of the current reporting period. Awarded units are presented net of performance adjustments.

Liability-Classified RSU

In Q1 2023, we granted RSU that were to be settled in cash if stockholder approval to increase our share reserve under the amended and restated 2015 Stock Plan was not obtained. In Q2 2023, the Company’s stockholders approved an amended and restated version of the 2015 Stock Plan and increased the maximum number of shares authorized for issuance. Upon such approval, all RSU previously accounted for as liability-classified awards, approximately 557,000 RSU, were reclassified to stockholders’ equity and accounted for prospectively as equity awards. There were no RSU liability-classified awards outstanding as of October 1, 2023.

Market-Based PSU

During YTD 2023, we granted PSU with a market condition that vest based on the Company’s relative total shareholder return (rTSR) as compared to a peer group of companies measured over a three-fiscal year performance period. Depending on the actual performance over the measurement period, an award recipient could receive up to 175% of the granted award. The grant date fair value of such awards is estimated using a Monte Carlo simulation, which includes assumptions for expected volatility, risk-free interest rate and dividend yield. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. The compensation expense for the

Table of Contents

awards is recognized over the requisite service period regardless of whether the market conditions are achieved. As of October 1, 2023, there were approximately 119,000 PSU with a rTSR market condition granted.

Stock Options

Stock option activity was as follows:

Units in thousands Options Weighted-Average
Exercise Price
Performance Stock Options(1)
Weighted-Average
Exercise Price
Outstanding at January 2, 2022 8 $ 66.42 17 $ 85.54
Granted 180 $ 330.25 — $ —
Exercised (1) $ 6.55 — $ —
Outstanding at October 2, 2022 187 $ 319.72 17 $ 85.54
Exercisable at October 2, 2022 8 $ 71.09 — $ —


Units in thousands	Options	Weighted-Average Exercise Price		Performance Options(1)	Weighted-Average Exercise Price
Outstanding at January 1, 2023	187	$	319.72	17	$	85.54

Exercised	(8)	$	71.09	(1)	$	16.69
Cancelled	(135)	$	330.25	—	$	—
Outstanding at October 1, 2023	44	$	330.25	16	$	87.74
Exercisable at October 1, 2023	18	$	330.25	—	$	—

_____________

(1)The number of units reflect awards that have been granted and for which it is assumed to be probable that the underlying performance goals will be achieved.

Other Liability-Classified Awards

We grant cash-based equity incentive awards to GRAIL employees. ~~On October 1, 2022, upon recommendation from GRAIL’s management, it was determined at a meeting of the Compensation Committee of Illumina’s Board of Directors that, for~~For purposes of valuation and performance measurement of the awards, GRAIL’s stand-alone valuation, as determined by GRAIL using a reasonable calculation and based on advice from independent valuation experts and analyses, ~~would be used for valuation and performance measurement purposes.~~

~~Table~~is used. The awards generally have terms of ~~Contents~~

four years with equal vesting annually, subject to continued employment through the vesting period.

Cash-based equity incentive award activity was as follows:


In millions
Outstanding at January ~~2, 2022~~1, 2023	$	~~184~~293
Granted	~~107~~116
Vested and paid in cash	~~(32)~~(65)
Cancelled	~~(33)~~(28)
Change in fair value	(8)
Outstanding at October ~~2, 2022~~1, 2023	$	~~226~~308
Estimated liability as of October ~~2, 2022~~1, 2023 (included in accrued liabilities)	$	2442

We recognized share-based compensation expense of $26 million and $72 million in Q3 2023 and YTD 2023, respectively, and $17 million and $46 million in Q3 2022 and YTD 2022, respectively. ~~No share-based compensation expense was recognized in Q3 2021 and YTD 2021.~~ As of October ~~2, 2022,~~1, 2023, approximately ~~$202~~$266 million of total unrecognized compensation cost related to awards issued to date was expected to be recognized over a weighted-average period of approximately ~~3.2~~2.8 years.

In connection with the acquisition of GRAIL, we assumed a performance-based award for which vesting is based on GRAIL’s future revenues. The award has an aggregate potential value of up to $78 million and expires, to the extent unvested, in August 2030. As of October ~~2, 2022,~~1, 2023, it was not probable that the performance conditions associated with the award will be achieved and, therefore, no share-based compensation expense, or corresponding liability, has been recognized in the condensed consolidated financial statements to-date.

Employee Stock Purchase Plan

The price at which common stock is purchased under the Employee Stock Purchase Plan (ESPP) is equal to 85% of the fair market value of the common stock on the first day of the offering period or purchase date, whichever is lower. During YTD ~~2022,~~2023, approximately ~~0.3~~0.4 million shares were issued under the ESPP. As of October ~~2, 2022,~~1, 2023, there were approximately ~~12.8~~12.4 million shares available for issuance under the ESPP.

Table of Contents

The assumptions used and the resulting estimate of weighted-average fair value per share for stock purchased under the ESPP during YTD 2023 were as follows:



Risk-free interest rate	0.78% - 5.54%
Expected volatility	41% - 51%
Expected term	0.5 - 1.1 year
Expected dividends	0		%
Weighted-average grant-date fair value per share	$	49.87

Share Repurchases

We did not repurchase any shares during YTD ~~2022.~~2023. As of October ~~2, 2022,~~1, 2023, authorizations to repurchase approximately $15 million of our common stock remained available under the $750 million share repurchase program authorized by our Board of Directors on February 5, 2020. The repurchases may be completed under a 10b5-1 plan or at management’s discretion.

Share-Based Compensation

Share-based compensation expense, which includes expense for both equity and liability-classified awards, reported in our condensed consolidated statements of operations was as follows:

In millions Q3 2022 Q3 2021 YTD 2022 YTD 2021
Cost of product revenue $ 7 $ 7 $ 20 $ 22
Cost of service and other revenue 2 1 4 3
Research and development 37 193 112 243
Selling, general and administrative 37 496 130 576
Share-based compensation expense before taxes 83 697 266 844
Related income tax benefits (18) (29) (60) (57)
Share-based compensation expense, net of taxes $ 65 $ 668 $ 206 $ 787

~~Table of Contents~~

In connection with the acquisition of GRAIL, we recognized, in Q3 2021, share-based compensation expense of $615 million related to the fair value of accelerated equity awards attributable to the post-combination period, of which $167 million was recorded in research and development expense and $448 million in selling, general and administrative expense.

In February 2021, we modified the metrics and reduced the maximum potential payouts for our performance stock units granted in 2019 and 2020. The PSU granted in 2019 vested on January 2, 2022 and the PSU granted in 2020 vests at the end of the three-year period ending on January 1, 2023. The modifications affected 52 employees with units granted in 2019, which resulted in total incremental share-based compensation expense of approximately $41 million, and 72 employees with units granted in 2020, which resulted in total incremental share-based compensation expense of approximately $65 million.

~~The assumptions used and the resulting estimate of weighted-average fair value per share for stock purchased under the ESPP during YTD 2022 were as follows:~~


	~~Employee Stock Purchase Rights~~
~~Risk-free interest rate~~	~~0.06% - 2.98%~~
~~Expected volatility~~	~~37% - 51%~~
~~Expected term~~	~~0.5 - 1.0 year~~
~~Expected dividends~~	0		%
~~Weighted-average grant-date fair value per share~~	$	~~50.22~~



In millions	Q3 2023		Q3 2022		YTD 2023		YTD 2022
Cost of product revenue	$	7	$	7	$	22	$	20
Cost of service and other revenue	2		2		5		4
Research and development	36		37		117		112
Selling, general and administrative	41		37		142		130
Share-based compensation expense, before taxes	86		83		286		266
Related income tax benefits	(19)		(18)		(65)		(60)
Share-based compensation expense, net of taxes	$	67	$	65	$	221	$	206

As of October ~~2, 2022,~~1, 2023, approximately ~~$538~~$582 million of total unrecognized compensation cost related to restricted stock, including RSU and PSU, stock options, including performance stock options, and ESPP shares issued to date was expected to be recognized over a weighted-average period of approximately 2.4 years.

Table of Contents


6. SUPPLEMENTAL BALANCE SHEET DETAILS

Accounts Receivable


In millions	In millions	October 2, 2022		January 2, 2022		In millions	October 1, 2023		January 1, 2023
Trade accounts receivable, gross	Trade accounts receivable, gross	$	632	$	651	Trade accounts receivable, gross	$	696	$	675
Allowance for credit losses	Allowance for credit losses	(4)		(3)		Allowance for credit losses	(6)		(4)
Total accounts receivable, net	Total accounts receivable, net	$	628	$	648	Total accounts receivable, net	$	690	$	671

Inventory


In millions	In millions	October 2, 2022		January 2, 2022		In millions	October 1, 2023		January 1, 2023
Raw materials	Raw materials	$	231	$	144	Raw materials	$	278	$	247
Work in process	Work in process	387		333		Work in process	423		386
Finished goods	Finished goods	29		32		Finished goods	35		28
Inventory, gross	Inventory, gross	647		509		Inventory, gross	736		661
Inventory reserve	Inventory reserve	(88)		(78)		Inventory reserve	(121)		(93)
Total inventory, net	Total inventory, net	$	559	$	431	Total inventory, net	$	615	$	568

~~Intangible Assets and Goodwill~~

We recorded a developed technology intangible asset of $23 million, with a useful life of 7 years, and a database intangible asset of $12 million, with a useful life of 7 years, as a result of an acquisition in Q2 2022. We are still finalizing the allocation of the purchase price as additional information is received to complete our analysis. We expect to finalize the valuation as soon as practicable, but no later than one year after the acquisition date.

~~Table of Contents~~

~~In addition, we recorded a licensed technology intangible asset of $180 million, with a useful life of 6.5 years, as a result of our litigation settlement with BGI in Q3 2022. Refer to note “7. Legal Proceedings” for additional details.~~

~~Changes to goodwill during YTD 2022 were as follows:~~


~~In millions~~
~~Balance as of January 2, 2022~~	$	~~7,113~~
~~Impairment~~	~~(3,914)~~
~~Acquisition~~	45
~~Measurement period adjustment~~	~~(6)~~
~~Balance as of October 2, 2022~~	$	~~3,238~~

We recorded a measurement period adjustment in Q3 2022 related to our GRAIL acquisition to decrease goodwill and increase deferred tax assets by $6 million, as a result of finalizing GRAIL’s U.S. tax returns. The measurement period adjustment was made to reflect facts and circumstances that existed as of the acquisition date. We finalized the allocation of the purchase price for the GRAIL acquisition in August 2022.

~~Impairment of Goodwill~~

We test goodwill for impairment annually, as of May, or more frequently if events or circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its carrying amount. We performed our annual impairment test in Q2 2022, as of May 2022. We performed a qualitative assessment for the Core Illumina reporting unit, noting no impairment. For the GRAIL reporting unit, we performed a quantitative assessment and determined a fair value for the reporting unit using a discounted cash flow model, which included assumptions for projected cash flows and a discount rate of 16.0%. The selected discount rate was determined using a weighted average cost of capital for risk factors specific to GRAIL and other market and industry data. The estimates and assumptions used represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Based on the quantitative test performed, the fair value of the GRAIL reporting unit exceeded its carrying value by $700 million and no goodwill impairment was recorded in Q2 2022.

On July 13, 2022, the EU General Court ruled that the European Commission has jurisdiction to review our acquisition of GRAIL. Additionally, on September 6, 2022, the European Commission issued its decision prohibiting the acquisition. Refer to note “~~7. Legal Proceedings~~” for additional details. These decisions, along with a continued and significant decrease in the Company’s stock price and market capitalization, led us to believe that a triggering event occurred and that an interim goodwill and intangible asset impairment test was required in Q3 2022.

Based on our interim analysis, we concluded that our GRAIL reporting unit’s carrying value exceeded its estimated fair value. As a result, we recorded $3,914 million of goodwill impairment related to our GRAIL reporting unit in Q3 2022, primarily due to the negative impact of current capital market conditions and a higher discount rate selected for the fair value calculation of the GRAIL reporting unit. No impairment was recorded for our Core Illumina reporting unit, noting its fair value exceeded its carrying value by more than $30 billion.

We performed our interim goodwill impairment test using a combination of both an income and a market approach to determine the fair value of each reporting unit. The income approach utilized the estimated discounted cash flows for each reporting unit while the market approach utilized comparable company information. Estimates and assumptions used in the income approach included projected cash flows for both the GRAIL and Core Illumina reporting units and a discount rate for each reporting unit. Discount rates were determined using a weighted average cost of capital for risk factors specific to each reporting unit and other market and industry data. For the GRAIL reporting unit, the discount rate selected was 22.0%. The estimates and assumptions used in our assessment represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. The assumptions used in our impairment analysis are inherently subject to uncertainty and we note that small changes in these assumptions could have a significant impact on the concluded value. In order to further validate the reasonableness of the fair

~~Table of Contents~~

~~values concluded for our reporting units, a reconciliation to market capitalization was performed by estimating a reasonable implied control premium and other market factors.~~

As a result of the impairment taken in Q3 2022, the carrying value of our GRAIL reporting unit now approximates its fair value. As such, changes in our future operating results, cash flows, share price, market capitalization or discount rates, as well as future regulatory decisions related to our acquisition of GRAIL, used when conducting future goodwill impairment tests could affect the estimated fair values of our reporting units and may result in additional goodwill impairment charges in the future. We will continue to monitor events occurring or circumstances changing which may suggest that goodwill should be reevaluated during interim periods prior to the annual impairment test. As of Q3 2022, remaining goodwill allocated to the GRAIL reporting unit was $2,178 million.

In conjunction with the interim goodwill impairment test, we also evaluated the IPR&D intangible asset, assigned to the GRAIL reporting unit, for potential impairment. We performed our interim impairment test by comparing the carrying value of the IPR&D intangible asset to its estimated fair value, which was determined by the income approach, using a discounted cash flow model. Estimates and assumptions used in the income approach included projected cash flows and a discount rate. These estimates and assumptions represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. Based on our interim impairment test, the carrying value of the IPR&D intangible asset did not exceed its estimated fair value. As a result, no impairment for the IPR&D intangible asset was recorded in Q3 2022.

We also performed a recoverability test for the definite-lived intangible assets assigned to the GRAIL reporting unit, which includes developed technology and trade name, noting no impairment in Q3 2022. Additionally, no impairment was noted for the definite-lived intangible assets assigned to our Core Illumina reporting unit.

Accrued Liabilities


In millions	In millions	October 2, 2022		January 2, 2022		In millions	October 1, 2023		January 1, 2023
Legal contingencies(1)	Legal contingencies(1)	$	453	$	—	Legal contingencies(1)	$	458	$	473
Contract liabilities, current portion	Contract liabilities, current portion	225		234		Contract liabilities, current portion	242		245
Accrued compensation expenses	Accrued compensation expenses	173		241		Accrued compensation expenses	195		188
Accrued taxes payable	Accrued taxes payable	81		98		Accrued taxes payable	65		97

Operating lease liabilities, current portion	Operating lease liabilities, current portion	77		71		Operating lease liabilities, current portion	85		76

Liability-classified equity incentive awards	Liability-classified equity incentive awards	24		11		Liability-classified equity incentive awards	42		36

Other, including warranties(2)	Other, including warranties(2)	109		106		Other, including warranties(2)	155		117
Total accrued liabilities	Total accrued liabilities	$	1,142	$	761	Total accrued liabilities	$	1,242	$	1,232

_____________

(1)See note “7. Legal Proceedings” for additional details.

(2)See table below for changes in the reserve for product warranties.

Changes in the reserve for product warranties were as follows:

In millions Q3 2022 Q3 2021 YTD 2022 YTD 2021
Balance at beginning of period $ 21 $ 16 $ 22 $ 13
Additions charged to cost of product revenue 5 5 17 20
Repairs and replacements (7) (6) (20) (18)
Balance at end of period $ 19 $ 15 $ 19 $ 15

~~Table of Contents~~



In millions	Q3 2023		Q3 2022		YTD 2023		YTD 2022
Balance at beginning of period	$	20	$	21	$	18	$	22
Additions charged to cost of product revenue	10		5		30		17
Repairs and replacements	(11)		(7)		(29)		(20)
Balance at end of period	$	19	$	19	$	19	$	19

We generally provide a one-year warranty on instruments. Additionally, we provide a warranty on consumables through the expiration date, which generally ranges from six to twelve months after the manufacture date. At the time revenue is recognized, an accrual is established for estimated warranty expenses based on historical experience as well as anticipated product performance. We periodically review the warranty reserve for adequacy and adjust the warranty accrual, if necessary, based on actual experience and estimated costs to be incurred. Warranty expense is recorded as a component of cost of product revenue.

Table of Contents

Restructuring

In Q2 2023, we implemented a cost reduction initiative that included workforce reductions, the consolidation of certain facilities and other actions to reduce expenses, all as part of a plan to realign operating expenses while maintaining focus on our innovation roadmap and sustainable long-term growth. In Q3 2023 and YTD 2023, we recorded restructuring charges primarily consisting of asset impairment charges and employee separation costs.

A summary of the pre-tax restructuring charges are as follows:


In millions	Q3 2023		YTD 2023
Employee separation costs	$	7	$	33

Asset impairment charges (1)	49		56
Other costs	2		2
Total restructuring charges (2)	$	58	$	91

_____________

(1)Primarily related to impairment of right-of-use assets and leasehold improvements for our i3 campus in San Diego, California.

(2)For Q3 2023, $55 million was recorded in SG&A expense, $2 million in R&D expense, with the remainder recorded in cost of revenue.

For YTD 2023 $74 million was recorded in SG&A expense, $13 million in R&D expense, with the remainder recorded in cost of revenue.

We fully exited our i3 campus in San Diego, California in Q3 2023, which resulted in a right-of-use asset impairment of $33 million in Q3 2023 and $38 million in YTD 2023, recognized in selling, general and administrative expense. The impairment was determined by comparing the fair value of the impacted right-of-use asset to the carrying value of the asset as of the impairment measurement date. The fair value of the right-of-use asset was estimated using the discounted future cash flows method, which includes estimates and assumptions for future sublease rental rates that reflect current sublease market conditions, as well as a discount rate. The estimates and assumptions used in our assessment represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. We also recorded $14 million in Q3 2023 and $16 million in YTD 2023 of leasehold improvement impairment, recognized in selling, general and administrative expense, related to the exit of our i3 campus. We continue to evaluate our options with respect to our campus in Foster City, California. As of October 1, 2023, we had assets, consisting primarily of right-of-use assets and leasehold improvements, related to our Foster City campus of approximately $182 million.

A summary of the restructuring liability is as follows:


In millions	Employee Separation Costs (1)		Other Costs		Total
Expense recorded in YTD 2023	$	33	$	2	$	35
Cash paid during YTD 2023	(30)		(1)		(31)

Amount recorded in accrued liabilities as of October 1, 2023	$	3	$	1	$	4

Estimated total restructuring costs to still be incurred	$	2	$	—	$	2

_____________

(1)It is expected that substantially all of the employee separation related restructuring charges will be incurred and paid by the end of 2023.

Goodwill and Intangible Assets

Table of Contents

In Q3 2023, we concluded the sustained decrease in the Company’s stock price and overall market capitalization during the quarter was a circumstance indicating the fair value of a reporting unit might be less than its carrying amount that required an interim goodwill and intangible impairment test be performed.

Based on our interim assessment, we concluded that our GRAIL reporting unit’s carrying value exceeded its estimated fair value. As a result, we recorded $712 million of goodwill impairment related to our GRAIL reporting unit in Q3 2023, primarily due to a decrease in the company’s consolidated market capitalization and a higher discount rate selected for the fair value calculation of the GRAIL reporting unit. No impairment was recorded for our Core Illumina reporting unit, noting its fair value exceeded its carrying value by more than $20 billion.

We performed our impairment test using a combination of an income and a market approach to determine the fair value of each reporting unit. The income approach utilized the estimated discounted cash flows for each reporting unit, while the market approach utilized comparable company information. Estimates and assumptions used in the income approach included projected cash flows and a discount rate for each reporting unit. Discount rates were determined using a weighted average cost of capital for risk factors specific to each reporting unit and other market and industry data. For GRAIL, the selected discount rate was 24.0%. The estimates and assumptions used in our assessment represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. The assumptions used are inherently subject to uncertainty and we note that small changes in these assumptions could have a significant impact on the concluded value. An increase of 50 to 100 basis points to the discount rate used in our assessment for GRAIL would have resulted in additional goodwill impairment of approximately $200 million to $350 million for GRAIL. In order to further validate the reasonableness of the fair values concluded for our reporting units, a reconciliation to market capitalization was performed by estimating a reasonable implied control premium and other market factors.

As a result of the impairment taken in Q3 2023, the carrying value of our GRAIL reporting unit now approximates its fair value. As such, changes in our future operating results, cash flows, share price (our share price has declined approximately 18% during the period October 1, 2023 to November 6, 2023), market capitalization or discount rates, as well as future regulatory decisions related to our acquisition of GRAIL, including the decision adopted by the European Commission on October 12, 2023 requiring us to divest GRAIL (refer to note “7. Legal Proceedings”), used when conducting future goodwill impairment tests could affect the estimated fair values of our reporting units and may result in additional impairment charges in the future. We will continue to monitor events and circumstances which may suggest that interim impairment indicators are present prior to the annual impairment test. As of October 1, 2023, remaining goodwill allocated to GRAIL was $1,466 million.

In conjunction with the interim goodwill impairment test, we also evaluated the in-process research and development (IPR&D) asset assigned to the GRAIL reporting unit for potential impairment. We performed our impairment test by comparing the carrying value of the IPR&D asset to its estimated fair value, which was determined by the income approach, using a discounted cash flow model. Estimates and assumptions used in the income approach, which represent a Level 3 measurement, included projected cash flows and a selected discount rate of 19.0%. Based on our impairment test, the carrying value of the GRAIL IPR&D asset exceeded its estimated fair value and we recorded an impairment of $109 million in Q3 2023, primarily due to a decrease in projected cash flows and a higher discount rate selected for the fair value calculation of the GRAIL IPR&D asset. As of October 1, 2023, the carrying value of the GRAIL IPR&D asset was $561 million. We also performed a recoverability test for the definite-lived intangible assets assigned to the GRAIL reporting unit, which includes developed technology and trade name, noting no impairment. No impairment was noted for Core Illumina definite-lived intangible assets.

Changes to goodwill during YTD 2023 were as follows:


In millions
Balance as of January 1, 2023 (1)	$	3,239
Impairment	(712)
Balance as of October 1, 2023	$	2,527

_____________

(1)The balance as of January 1, 2023 is inclusive of a $3,914 million goodwill impairment related to our GRAIL reporting unit in Q3 2022.

Table of Contents

Derivative Financial Instruments

We are exposed to foreign exchange rate risks in the normal course of business and use derivative financial instruments to partially offset this exposure. We do not use derivative financial instruments for speculative or trading purposes. Foreign exchange contracts are carried at fair value in other current assets, other assets, accrued liabilities, or other long-term liabilities, as appropriate, on the condensed consolidated balance sheets.

We use foreign exchange forward contracts to manage foreign currency risks related to monetary assets and liabilities denominated in currencies other than the U.S. dollar. These derivative financial instruments have terms of one month or less and are not designated as hedging instruments. Changes in fair value of these derivatives are recognized in other ~~(expense) income,~~expense, net, along with the re-measurement gain or loss on the foreign currency denominated assets or liabilities. As of October ~~2, 2022,~~1, 2023, we had foreign exchange forward contracts in place to hedge exposures in the euro, Japanese yen, Australian dollar, Canadian dollar, Singapore dollar, Chinese Yuan Renminbi, and British pound. As of October ~~2, 2022~~1, 2023 and January ~~2, 2022,~~1, 2023, the total notional amounts of outstanding forward contracts in place for these foreign currency purchases were ~~$472~~$912 million and ~~$462~~$485 million, respectively. On July 25, 2023, we entered into forward contracts for a total notional amount of €432 million to hedge the foreign currency exposure for the fine imposed by the European Commission on July 12, 2023.

We also use foreign currency forward contracts to hedge portions of our foreign currency exposure associated with forecasted revenue transactions. These derivative financial instruments have terms up to 24 months and are designated as cash flow hedges. Changes in fair value of our cash flow hedges are recorded as a component of accumulated other comprehensive income and are reclassified to revenue in the same period the underlying hedged transactions are recorded. Accordingly, we reclassified $16 million and $32 million to revenue in Q3 2022 and YTD 2022, respectively, and $3 million and $4 million in Q3 2021 and YTD 2021, respectively. The fair value of the foreign currency forward contracts recorded in total assets on the condensed consolidated balance sheets was $47 million and $19 million as of October 2, 2022 and January 2, 2022, respectively, of which $40 million and $19 million, respectively, was recorded within prepaid expenses and other current assets. The estimated net gains reported in accumulated other comprehensive income that are expected to be reclassified into earnings within the next 12 months are $40 million as of October 2, 2022. We regularly review the effectiveness of our cash flow hedges and consider them to be ineffective if it becomes probable that the forecasted transactions will not occur in the identified period. Changes in fair value of the ineffective portions of our cash flow hedges, if any, ~~will be~~are recognized in other ~~(expense) income,~~expense, net. As of October ~~2, 2022,~~1, 2023, we had foreign currency forward contracts in place to hedge exposures associated with forecasted revenue transactions denominated in the euro, Japanese yen, Australian dollar, Canadian dollar, and ~~Canadian dollar.~~Chinese Yuan Renminbi. As of October ~~2, 2022~~1, 2023 and January ~~2, 2022,~~1, 2023, the total notional amounts of outstanding cash flow hedge contracts in place for these foreign currency purchases were ~~$419~~$663 million and ~~$450~~$425 million, respectively. We reclassified $5 million and $9 million to revenue in Q3 2023 and YTD 2023, respectively, and $16 million and $32 million in Q3 2022 and YTD 2022, respectively. As of October 1, 2023, the fair value of the foreign currency forward contracts recorded in total assets and total liabilities was $27 million and $1 million, respectively. As of January 1, 2023, the fair value of the foreign currency forward contracts recorded in total assets and total liabilities was $8 million and $6 million, respectively. The estimated net gains reported in accumulated other comprehensive income that are expected to be reclassified into earnings within the next 12 months are $22 million as of October 1, 2023.


7. LEGAL PROCEEDINGS

We are involved in various lawsuits and claims arising in the ordinary course of business, including actions with respect to intellectual property, employment, and contractual matters. In connection with these matters, we assess, on a regular basis, the probability and range of possible loss based on the developments in these matters. A liability is recorded in the condensed consolidated financial statements if it is believed to be probable that a loss has been incurred and the amount of the loss can be reasonably estimated. Because litigation is inherently unpredictable and unfavorable resolutions could occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review outstanding legal matters to determine the adequacy of the liabilities accrued and related disclosures in consideration of many factors, which include, but are not limited to, past history, scientific and other evidence, and the specifics and status of each matter. We may change our estimates if our assessment of the various factors changes and the amount of ultimate loss may differ from our estimates, resulting in a material effect on our business, financial condition, results of operations, and/or cash flows.

~~Table of Contents~~

Acquisition of GRAIL

Our acquisition of GRAIL remains subject to ongoing legal and regulatory proceedings in the United States and in the European Union.

Table of Contents

On March 30, 2021, the U.S. Federal Trade Commission (the FTC) filed an administrative complaint and a motion for a preliminary injunction in the United States District Court for the District of Columbia. In both actions, the FTC alleged that our acquisition of GRAIL would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18. We filed an answer to the FTC’s complaint in federal district court on April 6, 2021, and in the administrative court on April 13, 2021. On April 20, 2021, the United States District Court for the District of Columbia granted our motion to transfer venue to the United States District Court for the Southern District of California. On May 28, 2021, the district court granted the FTC’s motion to dismiss the complaint without prejudice. The administrative trial commenced on August 24, 2021. On September 1, 2022, the administrative law judge (the ALJ) ruled in favor of Illumina and found that the acquisition of GRAIL did not violate Section 7 of the Clayton Act. In the decision, the ALJ found that the FTC’s complaint counsel had failed to prove its prima facie case that Illumina’s acquisition of GRAIL would result in harm to competition in a putative market for multi-cancer early detection (MCED) tests. The FTC’s complaint counsel appealed the ALJ’s decision to the full FTC on September 2, 2022. The appeal was fully briefed as of November 10, 2022 and oral argument occurred on ~~October 4, 2022,~~December 13, 2022. On March 31, 2023, the ~~FTC’s complaint counsel~~FTC issued an opinion and order (the FTC Order) requiring Illumina to divest GRAIL, reversing the ALJ’s ruling. On April 5, 2023, Illumina filed a petition for review of the FTC Order in the U.S. Court of Appeals for the Fifth Circuit. On April 24, 2023, the FTC granted a motion staying in its ~~opening~~entirety the FTC Order pending resolution of Illumina’s Fifth Circuit appeal. The appeal ~~brief.~~was fully briefed as of August 16, 2023 and oral argument occurred on September 12, 2023. We intend to continue to vigorously defend against the FTC action.

On April 19, 2021, the European Commission accepted a request for a referral of the GRAIL acquisition for European Union merger review, submitted by a Member State of the European Union (France), and joined by several other Member States (Belgium, Greece, Iceland, the Netherlands and Norway), under Article 22(1) of Council Regulation (EC) No 139/2004 (the EU Merger Regulation). The European Commission had never solicited referrals to take jurisdiction over an acquisition of a U.S. company that had no revenue in Europe. On April 29, 2021, we filed an action in the General Court of the European Union (the EU General Court) asking for annulment of the European Commission’s assertion of jurisdiction to review the acquisition under Article 22 of the EU Merger Regulation, as the acquisition does not meet the jurisdictional criteria under the EU Merger Regulation or under the national merger control laws of any Member State of the European Union. On December 16, 2021, the EU General Court held a hearing regarding the European Commission’s assertion of jurisdiction. On July 13, 2022, the EU General Court reached a decision in favor of the European Commission, holding that the European Commission has jurisdiction under the EU Merger Regulation to review the acquisition. On September 22, 2022, we filed an appeal in the Court of Justice of the European Union asking for annulment of the EU General Court’s decision.

On October 29, 2021, the European Commission adopted an order imposing interim measures (the Initial Interim Measures Order). As the Initial Interim Measures Order was set to expire on November 3, 2022, the European Commission adopted a new order imposing interim measures (the New Interim Measures Order) on October 28, 2022. On December 1, 2021, we filed an action with the EU General Court asking for annulment of the Initial Interim Measures Order. The hearing of that application has been stayed pending our appeal of the judgment of the EU General Court regarding the European Commission’s assertion of jurisdiction. On January 10, 2023, we filed an action with the EU General Court asking for annulment of the New Interim Measures Order. On January 20, 2023, the European Commission requested that these proceedings be stayed pending our appeal on jurisdiction. We submitted a filing indicating that we had no objections to the European Commission’s request, and the EU General Court stayed the proceedings on February 21, 2023.

On September 6, 2022, the European Commission announced that it had completed its Phase II review of the acquisition of GRAIL and adopted a final decision (the Prohibition Decision), which found that, in its view, our acquisition of GRAIL was incompatible with the internal market in Europe because it results in a significant impediment to effective competition. ~~Public statements made by~~On November 17, 2022, we filed an action with the EU General Court asking for annulment of the Prohibition Decision.

On October 12, 2023, the European Commission ~~in connection with the Prohibition Decision indicate that~~adopted a ~~subsequent~~ decision ~~is likely to be adopted by the European Commission that will order~~requiring us to (among other things) divest GRAIL, and replacing the interim measures set forth in the New Interim Measures Order with substantially equivalent transitional measures (the EC Divestment Decision). ~~Neither the Prohibition Decision nor such public statements indicate when any such EC Divestment Decision may be adopted.~~ We intend to appeal the ~~Prohibition Decision to~~EC Divestment Decision.

On July 12, 2023, the European Commission adopted a final decision finding that we breached the EU ~~General Court~~Merger Regulation by, in its view, acquiring the ~~applicable deadline. We also intend~~possibility to ~~appeal any EC Divestment Decision (if~~exert decisive influence over GRAIL and ~~when adopted by the European Commission) and, if necessary, to seek interim relief suspending the divestment of GRAIL until the final determination of these appeals.~~

~~Additionally, as a result of our decision to proceed with the completion of the acquisition of GRAIL~~exerting such influence during the pendency of the European Commission’s review ~~the~~(the Article 14(2)(b) Decision). The European Commission ~~will likely seek to impose~~therefore imposed a fine ~~on us~~ pursuant to Article 14(2)(b) of the EU Merger Regulation of ~~up to 10%~~approximately €432 million, representing the maximum fine of our consolidated annual revenues. On July 19, 2022, the European Commission issued a Statement of Objections alleging that we breached the EU Merger Regulation by completing our acquisition of GRAIL. As a result, we have accrued $453 million, included in accrued liabilities, as of Q3 2022, which represents 10% of our consolidated annual revenues for fiscal year ~~2021~~2022. We provided guarantees in ~~accordance with ASC 450,~~ ~~Contingencies~~.

~~BGI Genomics Co. Ltd.~~October 2023 to satisfy the obligation in lieu of cash payment while we appeal the European Commission’s jurisdictional decision and ~~its Affiliates~~

~~On June 27, 2019, we filed suit against BGI Genomics Co. Ltd (BGI) in the United States District Court for the Northern District~~fine decision. The fine is accruing interest at a rate of California, alleging that certain BGI sequencing products infringe our U.S. Patent No. 7,566,537 (‘537 patent) and U.S. Patent No. 9,410,200 (‘200 patent). BGI denied our claims and counterclaimed that our technology infringes U.S. Patent No. 9,944,984 (‘984 patent). We deny their allegations. On February 27, 2020, we filed a second patent infringement suit against BGI in the United States District Court for the Northern District of California alleging that BGI sequencing products infringed U.S. Patent 7,771,973 (‘973 patent), U.S. Patent 7,541,444 (‘444 patent), and U.S. Patent 10,480,025 (‘025 patent). On June 15, 2020, the Court granted our motions requesting preliminary injunctions against BGI, finding that our patents were likely valid and infringed by5.5% per annum,

Table of Contents

~~BGI’s chemistries. The injunction prohibited~~beginning in October 2023, while it is outstanding. As of October 1, 2023, we accrued $458 million, including related foreign currency gains (which were recorded in other expense, net), included in accrued liabilities. We appealed the ~~sale~~Article 14(2)(b) Decision on September 26, 2023.

SEC Inquiry Letter

In July 2023, we were informed that the staff of ~~infringing BGI sequencers~~the SEC was conducting an investigation relating to Illumina and ~~sequencing reagents~~was requesting documents and communications primarily related to Illumina’s acquisition of GRAIL and certain statements and disclosures concerning GRAIL, its products and its acquisition, and related to the conduct and compensation of certain members of Illumina and GRAIL management, among other things. Illumina is cooperating with the SEC in this investigation.

Derivative and Class Action Complaint

On October 17, 2023, a stockholder derivative and class action complaint captioned Icahn Partners LP, et al. v. deSouza, et al., purportedly brought on behalf of Illumina and public holders of Illumina’s common stock, was filed in the ~~U.S. On December 9, 2020, BGI filed~~Delaware Court of Chancery against certain current and former directors (including our former Chief Executive Officer). We are named as a ~~motion~~nominal defendant in the complaint. The lawsuit alleges the named directors breached their fiduciary duties by knowingly causing Illumina to ~~amend its answer~~unlawfully close the GRAIL acquisition, concealing material facts related to ~~our second suit~~the GRAIL acquisition and making inadequate disclosures. Prior to ~~include allegations that~~ the ~~‘444 and ‘973 patents are unenforceable under~~filing of the ~~doctrine of inequitable conduct; we deny BGI’s allegations. We deny that we owe any damages or ongoing royalty. On August 27, 2021, and September 9, 2021,~~complaint, the ~~Court issued its decisions on the summary judgment motions: (i) the Court granted our motion for summary judgment that we do~~purported stockholders did not ~~infringe BGI’s ‘984 patent; (ii) the Court granted our motion for summary judgment~~make a demand that our ~~‘444~~Board of Directors pursue the claims asserted therein. The complaint seeks damages, costs and ~~‘973 patents are not unenforceable; (iii)~~expenses, including attorney fees, the ~~Court granted our motion for summary judgment that BGI’s standard MPS products infringe all~~certification and consolidation of ~~our patents-in-suit: (iv)~~a putative class, the ~~Court granted our motion for summary judgment that BGI’s “Cool MPS” sequencing products infringe~~issuance of amended disclosures, the ~~‘973~~removal of conflicted directors and ~~‘444 patents,~~declaratory and ~~granted BGI’s motion for summary judgment that BGI’s “Cool MPS” sequencing products do not infringe~~other equitable relief. Since the ~~‘025 patent; and (v)~~lawsuit is brought in part on behalf of Illumina as a nominal defendant, the Court denied BGI’s motion for summary judgment that our ‘973 patent is invalid for lack of written description and enablement. Trial began on November 12, 2021, and the jury rendered a verdict on November 30, 2021. The jury found that the ‘537, ‘200, ‘973 patents and claims 9, 27, 31, 33, 34, 42, 47 of the ‘025 patent are valid andalleged damages were ~~willfully infringed~~allegedly suffered by BGI. The jury also ruled that the claim 4 of the ‘444 patent and claim 1 of the ‘025 patent were invalid as obvious. The jury awarded the Company $8 million in damages. On March 27, 2022, the Court issued a decision on post-trial motions. The Court denied BGI’s motions. The Court (i) upheld the jury’s award of $8 million and granted pre-judgment interest, (ii) upheld the jury’s finding that BGI’s infringement was willful, (iii) granted the Company’s request for a permanent injunction until the relevant patents expire; (iv) granted the Company’s request that claim 1 of the ‘025 patent is not invalid, but denied the request with respect to claim 4 of the ‘444 patent; and (v) denied the Company’s request for enhanced damages. On April 27, 2022, BGI appealed the judgment to the United States Court of Appeals for the Federal Circuit. The Company cross-appealed, including with respect to the denial of the Company’s request for enhanced damages.

On January 11, 2021, Complete Genomics, Inc. (CGI), BGI Americas Corp., and MGI Americas, Inc. filed a complaint in the United States District Court for the Northern District of California alleging the Company and its subsidiary Illumina Cambridge Ltd. violated federal antitrust and state unfair competition laws. CGI and these affiliates alleged that the Company fraudulently withheld a prior art reference that was material to patentability for the ‘444 and ‘973 patents. They also alleged that our infringement claims of the ‘025 against BGI’s “Cool MPS” chemistry were objectively baseless. The Company deniesus. We deny the allegations in the ~~complaint. On March 30, 2021, the Court stayed the antitrust case pending resolution of the underlying patent infringement suit taking place in the same court.~~

~~On May 28, 2019, CGI filed suit against us in the United States District Court for the District of Delaware alleging that our two-channel sequencing systems, including the NovaSeq, NextSeq,~~complaint and MiniSeq systems, infringe certain claims of U.S. Patent No. 9,222,132. We denied CGI’s allegations and counterclaimed for infringement by CGI, BGI Americas Corp., and MGI Americas, Inc. of U.S. Patent No. 9,303,290, U.S. Patent No. 9,217,178, and U.S. Patent No. 9,970,055. On August 15, 2019, CGI filed a motion to dismiss our counterclaims. On August 29, 2019, we filed our Opposition to the Motion to Dismiss. The Court denied and granted the motion in part, denying the motion as to our claims for inducing infringement and granting it for contributory infringement. The Court gave us leave to file an amended complaint to attempt to cure the alleged deficiencies as to contributory infringement. On July 1, 2020, CGI amended its complaint to add claims of infringement of U.S. Patent No. 10,662,473 by our two-channel sequencing systems. We deny these allegations. CGI requested approximately $334 million in alleged past damages and an average ongoing royalty of at least 5.5% on sales of the accused two-channel sequencing instruments and chemistry in the U.S. until the patents-in-suit expire on January 28, 2029. We denied that we owed any damages or ongoing royalty. On October 22, 2021, pursuant to the Court’s local rules, the Company sought leave to file a motion for summary judgment of non-infringement of the CGI patents-in-suit. CGI sought leave to file a motion for summary judgment against the Company’s invalidity defense based on prior invention. On January 14, 2022, the Court denied the Company and CGI’s motions for leave to file for summary judgment. Trial began on April 25, 2022.

On May 6, 2022, the jury in the U.S. District Court for the District of Delaware rendered a verdict that we willfully infringed U.S. Patent Nos. 9,222,132 and 10,662,473 owned by CGI, and awarded approximately $334 million to CGI in past damages. The jury also invalidated three patents owned by us, namely, U.S. Patent Nos. 9,217,178; 9,303,290; and 9,970,055. On July 14, 2022, we entered into a Settlement and License Agreement with BGI and CGI (the “Agreement”). The Agreement resolves all claims in Complete Genomics, Inc. v. Illumina, Inc., Case No. C.A. No. 19-970-MN (D. Del.). The Agreement also resolves all claims in Illumina, Inc. and Illumina Cambridge Ltd. v. BGI Genomics Co., Ltd., BGI Americas Corp., MGI Tech Co., Ltd., MGI Americas Inc., and Complete Genomics, Inc., Case No. 3:19-cv-03770-WHO (N.D. Cal.) and Illumina, Inc. and Illumina Cambridge Ltd. v. BGI Genomics Co., Ltd., BGI Americas Corp., MGI Tech Co., Ltd., MGI Americas Inc., and Complete Genomics, Inc., Case No. 3:20-

~~Table of Contents~~

cv-01465-WHO (N.D. Cal.), as well as related Appeal Nos. 2022-1733, 2022-1735 and 2022-1742, 2022-1743 pending in the United States Court of Appeals for the Federal Circuit, with the exception that the permanent injunction entered on April 11, 2022 against BGI remains in effect with a revised expiration date of January 1, 2023, with respect to BGI’s StandardMPS chemistry. The Agreement further resolves all antitrust claims against us in Complete Genomics, Inc., BGI Americas Corp. and MGI Americas, Inc. v. Illumina, Inc. and Illumina Cambridge Ltd., Case No. 21-cv-00217 (N.D. Cal.) and that complaint was dismissed with prejudice. Pursuant to the terms of the Agreement, the Company agreed to pay Complete Genomics a one-time payment of $325 million, with the parties agreeing that the judgment against BGI and the judgment against the Company in the above-referenced litigations are satisfied in total. In addition, the Company received from BGI a fully paid-up license to U.S. Patent Nos. 8,617,811, 9,222,132, 9,523,125, 10,662,473, 11,098,356 and 11,214,832, U.S. Patent Application Nos. 61/024,396, 61/024,110, 16/882,461, 17/407,935 and 17/523,706, and U.S. patents and patent applications related to each of the foregoing U.S. patents and patent applications until their expiration (“the 2-channel technology patents”). Our license allows the Company to use the 2-channel technology in all its current and future platforms with no additional royalties owed. BGI received from us a fully paid-up license to U.S. Patent Nos. 9,217,178, 9,303,290 and 9,970,055 (“the image mix patents”) and U.S. patents and applications related to each of the foregoing U.S. patents until their expiration. The parties agreed to a litigation standstill for patent and antitrust actions in the United States and its territories until October 1, 2025, as set forth in the Agreement. The standstill does not apply to the parties’ patents or patent applications related to non-invasive prenatal testing, nor to any intellectual property of Grail, Inc., related to multi-cancer early detection. None of the parties make any admission of liability in entering into the Agreement.

We allocated the $325 million payment on a relative fair value basis, resulting in $180 million capitalized as an intangible asset for the value of the license, which is amortized over a period of 6.5 years on a straight-line basis, $150 million allocated to the release of past damages claimed, and a $5 million gain for damages awarded to us. The fair value of the license was estimated using a discounted cash flow model, which included assumptions for projected revenues covered by the license, an estimated royalty rate and a discount rate. The fair value of the past damages claimed was estimated based on applicable historical revenues and an estimated royalty rate. These inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. As of Q2 2022, we had accrued $156 million for the release of past damages claimed. The settlement of the litigation resulted in a gain of $6 million, calculated as the difference between the accrual released and the amount of payment allocated to the release of past damages claimed.

~~RavGen~~

On December 3, 2020, RavGen filed a patent infringement suit against the Company claiming the Company’s use of Streck, Inc. sample collection tubes in its Verifi, Verifi Plus, and VeriSeq NIPT and liquid biopsy oncology products infringe U.S. Patent Nos. 7,332,277 and 7,727,720 (RavGen, Inc. v. Illumina, Inc., United States District Court for the District of Delaware, Case No. 1:20-cv-01644-UNA). The patents-in-suit are directed to the use of a sample-stabilizing agent that inhibits the lysis of cells. RavGen is seeking, among other things, an unspecified amount of damages, an injunction, and reasonable attorneys’ fees. The patents expire March 13, 2023.

~~On January 27, 2021, the Company filed its Answer and Counterclaims denying all allegations in the Complaint and seeking declaratory judgment of non-infringement and invalidity.~~

On July 20, 2021, the Company filed Petitions for Inter Partes Review (IPR) of the ‘277 and ‘720 patents-in-suit with the US Patent Trial and Appeal Board seeking to invalidate certain claims of the patents (PTAB) (IPR2021-01272 and IPR2021-01271). On January 26, 2022, the PTAB instituted the IPRs. The PTAB’s final written decisions in the IPRs are due by January 26, 2023.

~~On March 1, 2022, the District Court granted the Company’s motion to stay the litigation pending resolution of the IPRs. The Company intends~~intend to vigorously defend ~~against Ravgen’s claims.~~

the litigation. In ~~parallel, on December 15, 2020,~~light of the ~~Company requested Streck, Inc. to indemnify the Company in the RavGen litigation. On January 6, 2021, Streck responded, denying any obligation to indemnify the Company. Streck also requested~~fact that the ~~Company stay its indeminification request pending resolution~~lawsuit is in an early stage, we cannot predict the ultimate outcome of the ~~underlying patent infringement~~ suit. ~~The Company and Streck executed a tolling agreement effective April 2, 2021, staying the Company’s indemnification claim pending resolution of the underlying patent suit.~~

~~Table of Contents~~

~~We currently cannot estimate the possible loss or range of loss, if any, that may result from RavGen’s claims against us.~~


8. INCOME TAXES

Our effective tax rate may vary from the U.S. federal statutory tax rate due to the change in the mix of earnings in tax jurisdictions with different statutory rates, benefits related to tax credits, and the tax impact of non-deductible expenses and other permanent differences between income before income taxes and taxable income.

Our effective tax rates for Q3 ~~2022~~2023 and YTD ~~2022~~ 2023were ~~(4.0)%~~3.6% and ~~(2.3)~~(3.8)%, respectively, compared to ~~24.7%~~(4.0)% and ~~18.6%~~(2.3)% in Q3 ~~2021~~2022 and YTD ~~2021,~~2022, respectively. The variance from the U.S. federal statutory tax rate of 21% in Q3 ~~2022~~2023 and YTD ~~2022~~2023 was primarily ~~because of~~attributable to the ~~$822~~$149 million income tax expense impact from the impairment of goodwill, which is nondeductible for tax purposes, the ~~$64~~$20 million and ~~$91~~$84 million income tax ~~impacts~~expense impact of research and development expense capitalization for tax purposes, respectively, and the ~~$30~~$38 million and ~~$60~~$63 million income tax ~~impacts~~expense impact of GRAIL pre-acquisition net operating losses on global intangible low-taxed income (GILTI) and the utilization of U.S. foreign tax credits, respectively. This was partially offset by the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in ~~Singapore and~~Singapore.

Historically, we calculated the ~~United Kingdom.~~

~~In YTD 2022, the variance from the U.S. federal statutory~~provision/(benefit) for income taxes for interim periods utilizing an estimated annual effective tax rate ~~of 21% was also impacted by the $95 million tax impact from the potential European Commission fine related~~applied to the ~~GRAIL acquisition, which is nondeductible~~income/(loss) for the reporting period, except in Q2 2023 when a year-to-date effective tax ~~purposes.~~rate method was utilized. We determined the estimated annual effective tax rate method would provide a more reliable estimate of the provision for income taxes for Q3 2023 and YTD 2023, since minor changes in the estimated income/(loss) before income taxes would not result in significant changes in the estimated annual effective tax rate.

As of October ~~2, 2022~~1, 2023 and January ~~2, 2022,~~1, 2023, prepaid income taxes, included within prepaid expenses and other current assets on the condensed consolidated balance sheets, were ~~$54~~$78 million and ~~$101~~$116 million, respectively. ~~The decrease primarily relates to the tax expense recorded in Q3 2022.~~

Table of Contents


9. SEGMENT INFORMATION

We have two reportable segments, Core Illumina and GRAIL. We report segment information based on the management approach, which designates the internal reporting used by the Chief Operating Decision Maker (CODM) for making decisions and assessing performance as the source of our reportable segments. The CODM allocates resources and assesses the performance of each operating segment using information about its revenue and income (loss) from operations. Our CODM does not evaluate our operating segments using discrete asset information. We do not allocate expenses between segments. Core Illumina sells products and provides services to GRAIL, and vice versa, in accordance with contractual agreements between the entities.

Core Illumina:

Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Core Illumina includes all of our operations, excluding the results of GRAIL.

GRAIL:

GRAIL is a healthcare company focused on early detection of multiple cancers. ~~We acquired GRAIL on August 18, 2021. We have included the financial results of GRAIL in our condensed consolidated financial statements from the date of acquisition.~~

~~Table of Contents~~

In millions Q3 2022 Q3 2021 YTD 2022 YTD 2021
Revenue:
Core Illumina $ 1,110 $ 1,106 $ 3,487 $ 3,325
GRAIL 10 2 32 2
Eliminations (5) — (18) —
Consolidated revenue $ 1,115 $ 1,108 $ 3,501 $ 3,327
Income (loss) from operations:
Core Illumina $ 445 $ 205 $ 411 $ 586
GRAIL (4,101) (750) (4,460) (750)
Eliminations (1) — (3) —
Consolidated loss from operations $ (3,657) $ (545) $ (4,052) $ (164)



In millions	Q3 2023		Q3 2022		YTD 2023		YTD 2022
Revenue:
Core Illumina	$	1,106	$	1,110	$	3,341	$	3,487
GRAIL	21		10		62		32
Eliminations	(8)		(5)		(21)		(18)
Consolidated revenue	$	1,119	$	1,115	$	3,382	$	3,501







Income (loss) from operations:
Core Illumina	$	262	$	445	$	519	$	411
GRAIL	(1,015)		(4,101)		(1,424)		(4,460)
Eliminations	(1)		(1)		—		(3)
Consolidated loss from operations	$	(754)	$	(3,657)	$	(905)	$	(4,052)

Total other ~~(expense) income,~~expense, net primarily relates ~~primarily~~ to Core Illumina and we do not allocate income taxes to our segments.

In millions October 2,
2022 January 2,
2022
Total assets:
Core Illumina $ 5,626 $ 5,571
GRAIL 5,637 9,649
Eliminations (7) (3)
Consolidated total assets $ 11,256 $ 15,217

3028

Table of Contents


MANAGEMENT’S DISCUSSION & ANALYSIS

Our Management’s Discussion and Analysis (MD&A) will help readers understand our results of operations, financial condition, and cash flow. It is provided in addition to the accompanying condensed consolidated financial statements and notes. This MD&A is organized as follows:

•Management’s Overview and Outlook. High level discussion of our operating results and significant known trends that affect our business.

•Results of Operations. Detailed discussion of our revenues and expenses.

•Liquidity and Capital Resources. Discussion of key aspects of our condensed consolidated statements of cash flows, changes in our financial position, and our financial commitments.

•Critical Accounting Policies and Estimates. Discussion of significant changes since our most recent Annual Report on Form 10-K that we believe are important to understanding the assumptions and judgments underlying our condensed consolidated financial statements.

•Recent Accounting Pronouncements. Summary of recent accounting pronouncements applicable to our condensed consolidated financial statements.

•Quantitative and Qualitative Disclosure About Market Risk. Discussion of our financial instruments’ exposure to market risk.

Our discussion of our results of operations, financial condition, and cash flow for Q3 ~~2021~~2022 and YTD ~~2021~~2022 can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” within our filing of Form 10-Q for the fiscal quarter ended October ~~3, 2021.~~2, 2022.

This MD&A discussion contains forward-looking statements that involve risks and uncertainties. See “Consideration Regarding Forward-Looking Statements” preceding the Condensed Consolidated Financial Statements section of this report for additional factors relating to such statements. This MD&A should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and our Annual Report on Form 10-K for the fiscal year ended January ~~2, 2022.~~1, 2023. Operating results are not necessarily indicative of results that may occur in future periods.

MANAGEMENT’S OVERVIEW AND OUTLOOK

This overview and outlook provide a high-level discussion of our operating results and significant known trends that affect our business. We believe that an understanding of these trends is important to understanding our financial results for the periods being reported herein as well as our future financial performance. This summary is not intended to be exhaustive, nor is it intended to be a substitute for the detailed discussion and analysis provided elsewhere in this report.

About Illumina

Our focus on innovation has established us as ~~the~~a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.

Our customers include leading genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.

Our comprehensive line of products addresses the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests. This portfolio of leading-edge sequencing and array-based solutions addresses a range of genomic complexity and throughput, enabling researchers and clinical practitioners to select the best solution for their scientific challenge.

3129

Table of Contents

On August 18, 2021, we acquired GRAIL, a healthcare company focused on early detection of multiple cancers. GRAIL’s Galleri blood test detects various types of cancers before they are symptomatic. We believe our acquisition of GRAIL will accelerate the adoption of next-generation sequencing based early multi-cancer detection tests, enhance our position in Clinical Genomics, and increase our directly accessible total addressable market. The acquisition is subject to ongoing legal proceedings and, currently, GRAIL ~~is currently being~~must be held and operated ~~as a separate company, with oversight provided~~separately and independently from Illumina pursuant to the transitional measures ordered by ~~an appointed, independent monitoring trustee.~~the European Commission in the EC Divestment Decision, following the prohibition of our acquisition of GRAIL on September 6, 2022. See note “7. Legal Proceedings” for further details.

With respect to GRAIL, we have retained advisors and are preparing for sale and capital markets transaction options in accordance with the European Commission’s divestiture order. In parallel, ongoing appeals preserve flexibility for any divestiture of GRAIL and future transactions.

We have ~~included~~two reportable segments, Core Illumina and GRAIL. Core Illumina relates to our core operations, excluding the ~~financial~~ results of ~~GRAIL in our condensed consolidated financial statements from the date of acquisition. GRAIL is a separate reportable segment.~~GRAIL. See note “9. Segment Information” for additional details.

Our financial results have been, and will continue to be, impacted by several significant trends, which are described below. While these trends are important to understanding and evaluating our financial results, this discussion should be read in conjunction with our condensed consolidated financial statements and the notes thereto within the Condensed Consolidated Financial Statements section of this report, and the other transactions, events, and trends discussed in “Risk Factors” within the Other Key Information section of this report.

Financial Overview

Since 2020, the COVID-19 pandemic and international efforts to control its spread have significantly curtailed the movement of people, goods, and services worldwide, including in the regions where we sell our products and services and conduct our business operations. In addition, armed conflict between Russia and Ukraine, which began in 2022, and the sanctions imposed by the U.S. and other countries, ~~may impact~~has impacted our ability to ship products into affected ~~regions.~~regions and to designated customers. Furthermore, macroeconomic factors such as inflation, exchange rates and concerns about an economic downturn, and competitive challenges in our China region, have impacted both Illumina directly and our customers’ ~~behavior, and we expect these factors to continue to impact our business through 2022.~~behavior. For example, some customers experienced supply chain pressures that delayed their lab expansions and others are managing inventory and capital more conservatively. We expect these factors to continue to impact our sales and results of operations for the remainder of 2023, the size and duration of which is significantly uncertain.

Financial highlights for YTD ~~2022~~2023 included the following:

•Revenue ~~increased 5%~~decreased 3% in YTD 2023 to $3,382 million compared to $3,501 million in YTD 2022 ~~to $3,501 million compared to $3,327 million in YTD 2021~~ primarily due to ~~growth~~decreases in sequencing consumables revenue and sequencing instruments ~~as well as~~revenue, partially offset by an increase in service and other revenue. We expect ~~our~~ revenue to ~~be flat~~decrease 2% to ~~1% higher~~3% in ~~2022~~2023 compared to ~~2021.~~2022.

•Gross profit as a percentage of revenue (gross margin) was 61.2% in YTD 2023 compared to 65.7% in YTD ~~2022 compared to 70.2% in YTD 2021.~~2022. The decrease in gross margin was driven primarily by less fixed cost leverage on lower manufacturing volumes, lower instrument margins due to the ~~gross loss incurred by GRAIL~~NovaSeq X launch in ~~YTD 2022.~~Q1 2023, and unfavorable product mix. Our gross margin depends on many factors, including: market conditions that may impact our pricing; sales mix changes among consumables, instruments, services, and development and licensing revenue; product mix changes between established products and new products; excess and obsolete inventories; royalties; our cost structure for manufacturing operations relative to volume; freight costs; and product support obligations.

•Loss from operations ~~as a percentage of revenue~~ was ~~(115.7)%~~$905 million in YTD ~~2022~~2023 compared to ~~(5.0)%~~$4,052 million in YTD ~~2021.~~2022. The decrease was primarily due to ~~goodwill impairment related to GRAIL, a legal contingency recorded related to the potential European Commission fine, a loss related to our settlement with BGI and~~ a decrease in operating expense of $3,377 million, which included significant decreases in goodwill and intangible impairment of $3,093 million and legal contingency and settlement of $584 million, partially offset by a $230 million decrease in gross ~~margin.~~profit. We ~~expect our operating expenses to~~ continue to ~~grow~~focus on ~~an absolute basis~~our cost reduction initiatives to accelerate progress toward higher margins and create flexibility for further investment in ~~2022 compared to 2021.~~high-growth areas.

Table of Contents

•Our effective tax rate was (3.8)% in YTD 2023 compared to (2.3)% in YTD ~~2022 compared to 18.6% in YTD 2021.~~2022. The variance from the U.S. federal statutory tax rate of 21% was primarily because of the income tax ~~impacts~~expense impact of the impairment of goodwill, ~~and the potential European Commission fine related to the GRAIL acquisition~~ which ~~are~~is nondeductible for tax purposes, the income tax expense impact of research and development expense capitalization for tax purposes, and the income tax expense impact of GRAIL pre-acquisition net operating losses on GILTI and the utilization of U.S. foreign tax credits. This was partially offset by the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in ~~Singapore and the United Kingdom.~~Singapore.

•We ended Q3 ~~2022~~2023 with cash, cash equivalents, and short-term investments totaling ~~$1.0 billion as of October 2, 2022,~~$933 million, of which approximately ~~$537~~$499 million was held by our foreign subsidiaries.

~~Table of Contents~~

RESULTS OF OPERATIONS

To enhance comparability, the following table sets forth unaudited condensed consolidated statement of operations data for the specified reporting periods, stated as a percentage of total ~~revenue~~revenue.(1).


		Q3 2022		Q3 2021		YTD 2022		YTD 2021			Q3 2023		Q3 2022		YTD 2023		YTD 2022
Revenue:	Revenue:									Revenue:
Product revenue	Product revenue	86.4	%	88.3	%	86.8	%	87.3	%	Product revenue	84.1	%	86.4	%	84.7	%	86.8	%
Service and other revenue	Service and other revenue	13.6		11.7		13.2		12.7		Service and other revenue	15.9		13.6		15.3		13.2
Total revenue	Total revenue	100.0		100.0		100.0		100.0		Total revenue	100.0		100.0		100.0		100.0
Cost of revenue:	Cost of revenue:									Cost of revenue:
Cost of product revenue	Cost of product revenue	25.1		23.8		24.7		23.5		Cost of product revenue	26.2		25.1		26.1		24.7
Cost of service and other revenue	Cost of service and other revenue	6.5		5.1		6.0		5.4		Cost of service and other revenue	8.5		6.5		8.4		6.0
Amortization of acquired intangible assets	Amortization of acquired intangible assets	4.1		1.6		3.6		0.9		Amortization of acquired intangible assets	4.2		4.1		4.3		3.6
Total cost of revenue	Total cost of revenue	35.7		30.5		34.3		29.8		Total cost of revenue	38.9		35.7		38.8		34.3
Gross profit	Gross profit	64.3		69.5		65.7		70.2		Gross profit	61.1		64.3		61.2		65.7
Operating expense:	Operating expense:									Operating expense:
Research and development	Research and development	29.1		39.4		27.8		25.1		Research and development	28.1		29.1		30.0		27.8
Selling, general and administrative	Selling, general and administrative	13.1		79.3		24.7		50.1		Selling, general and administrative	27.0		13.1		33.3		24.7
Goodwill and intangible impairment										Goodwill and intangible impairment	73.4		351.0		24.3		111.8
Legal contingency and settlement	Legal contingency and settlement	(1.0)		—		17.1		—		Legal contingency and settlement	(0.1)		(1.0)		0.4		17.1
Goodwill impairment		351.0		—		111.8		—

Total operating expense	Total operating expense	392.2		118.7		181.4		75.2		Total operating expense	128.4		392.2		88.0		181.4
Loss from operations	Loss from operations	(327.9)		(49.2)		(115.7)		(5.0)		Loss from operations	(67.3)		(327.9)		(26.8)		(115.7)
Other income (expense):	Other income (expense):									Other income (expense):
Interest income	Interest income	0.3		—		0.1		—		Interest income	1.2		0.3		1.4		0.1
Interest expense	Interest expense	(0.5)		(1.3)		(0.5)		(1.5)		Interest expense	(1.7)		(0.5)		(1.7)		(0.5)

Other (expense) income, net		(1.1)		88.4		(2.9)		30.4
Total other (expense) income, net		(1.3)		87.1		(3.3)		28.9
(Loss) income before income taxes		(329.2)		37.9		(119.0)		23.9
Provision for income taxes		12.9		9.3		2.8		4.4
Net (loss) income		(342.1)	%	28.6	%	(121.8)	%	19.5	%
Other expense, net										Other expense, net	(2.1)		(1.1)		(1.0)		(2.9)
Total other expense, net										Total other expense, net	(2.6)		(1.3)		(1.3)		(3.3)
Loss before income taxes										Loss before income taxes	(69.9)		(329.2)		(28.1)		(119.0)
(Benefit) provision for income taxes										(Benefit) provision for income taxes	(2.5)		12.9		1.1		2.8
Net loss										Net loss	(67.4)	%	(342.1)	%	(29.2)	%	(121.8)	%

_____________

(1)Percentages may not recalculate due to rounding.

3331

Table of Contents

Revenue


Dollars in millions	Dollars in millions	Q3 2022		Q3 2021		Change		% Change		YTD 2022		YTD 2021		Change		% Change		Dollars in millions	Q3 2023		Q3 2022		Change		% Change		YTD 2023		YTD 2022		Change		% Change

Core Illumina:	Core Illumina:																	Core Illumina:
Consumables	Consumables	$	801	$	794	$	7	1	%	$	2,478	$	2,347	$	131	6	%	Consumables	$	766	$	801	$	(35)	(4)	%	$	2,344	$	2,478	$	(134)	(5)	%
Instruments	Instruments	167		184		(17)		(9)		578		556		22		4		Instruments	182		167		15		9		539		578		(39)		(7)
Total product revenue	Total product revenue	968		978		(10)		(1)		3,056		2,903		153		5		Total product revenue	948		968		(20)		(2)		2,883		3,056		(173)		(6)
Service and other revenue	Service and other revenue	142		128		14		11		431		422		9		2		Service and other revenue	158		142		16		11		458		431		27		6
Total Core Illumina revenue	Total Core Illumina revenue	1,110		1,106		4		—		3,487		3,325		162		5		Total Core Illumina revenue	1,106		1,110		(4)		—		3,341		3,487		(146)		(4)
GRAIL:	GRAIL:																	GRAIL:
Service and other revenue	Service and other revenue	10		2		8		400		32		2		30		1,500		Service and other revenue	21		10		11		110		62		32		30		94
Eliminations	Eliminations	(5)		—		(5)		100		(18)		—		(18)		100		Eliminations	(8)		(5)		(3)		60		(21)		(18)		(3)		17
Total consolidated revenue	Total consolidated revenue	$	1,115	$	1,108	$	7	1	%	$	3,501	$	3,327	$	174	5	%	Total consolidated revenue	$	1,119	$	1,115	$	4	—		$	3,382	$	3,501	$	(119)	(3)	%

The ~~increases~~decrease in Core Illumina consumables revenue in Q3 ~~2022~~2023 and YTD ~~2022 were~~2023 was primarily due to ~~increases~~a decrease in sequencing consumables revenue of $2$30 million and ~~$130~~$127 million, respectively, driven primarily by ~~growth in the instrument installed base, partially offset by~~lower NovaSeq 6000 consumables pull-through as some of our high throughput customers continue to transition to NovaSeq X, as well as the impact of ~~challenging~~ macroeconomic ~~factors~~conditions on our customers. Core Illumina instruments revenue decreased in Q3 2022 primarily due to fewer shipments of our NovaSeq 6000 instrument, partially offset by increased shipments of our NextSeq 1000/2000 instrument.customer purchasing power and project planning. Core Illumina instruments revenue increased in ~~YTD 2022, primarily~~Q3 2023 due to an increase in sequencing instruments revenue of ~~$19~~$17 million, driven primarily by ~~increased~~ shipments of our NovaSeq ~~6000~~X instrument, ~~partially~~ offset by fewer shipments of our NovaSeq 6000 and NextSeq ~~1000/2000 instrument.~~instruments. Core Illumina instruments revenue decreased in YTD 2023 due to a decrease in sequencing instruments revenue of $38 million, driven primarily by fewer shipments of our NovaSeq 6000, NextSeq and MiSeq instruments, partially offset by shipments of NovaSeq X that launched in Q1 2023. Core Illumina service and other revenue increased in Q3 ~~2022~~2023 and YTD ~~2022,~~2023 primarily due to increased revenue from extended maintenance service contracts ~~in Q3 2022 and YTD 2022. For YTD 2022, the~~on a growing installed base. The increase in ~~service and other revenue~~YTD 2023 was partially offset by ~~revenue~~decreases in revenues from ~~a patent litigation settlement in Q2 2021.~~development and licensing agreements and genotyping services. Additionally, Core Illumina revenue was favorably impacted by $9 million in Q3 2023 and adversely impacted by ~~$27 million in Q3 2022 and $59~~$26 million in YTD ~~2022~~2023, due to ~~unfavorable~~ foreign exchange rate fluctuations, which ~~is net of amounts~~included $5 million and $9 million reclassified to revenue ~~of $16 million and $32 million~~ in Q3 ~~2022~~2023 and YTD ~~2022,~~2023, respectively, related to our cash flow hedges.

GRAIL service and other revenue ~~for~~increased $11 million, or 110%, and $30 million, or 94%, in Q3 ~~2022, YTD 2022 and Q3 2021~~2023 and YTD ~~2021, for the period subsequent to the acquisition, related~~2023, respectively, primarily due to sales of Galleri.

Gross Margin


Dollars in millions	Dollars in millions	Q3 2022			Q3 2021			Change		% Change		YTD 2022			YTD 2021			Change		% Change		Dollars in millions	Q3 2023			Q3 2022			Change		% Change		YTD 2023			YTD 2022			Change		% Change
Gross profit (loss):	Gross profit (loss):																					Gross profit (loss):
Core Illumina	Core Illumina	$	753		$	781		$	(28)	(4)	%	$	2,405		$	2,348		$	57	2	%	Core Illumina	$	715		$	753		$	(38)	(5)	%	$	2,161		$	2,405		$	(244)	(10)	%
GRAIL	GRAIL	(32)			(11)			(21)		191		(91)			(11)			(80)		727		GRAIL	(27)			(32)			5		(16)		(77)			(91)			14		(15)
Eliminations	Eliminations	(4)			—			(4)		100		(14)			—			(14)		100		Eliminations	(4)			(4)			—		—		(14)			(14)			—		—
Consolidated gross profit	Consolidated gross profit	$	717		$	770		$	(53)	(7)	%	$	2,300		$	2,337		$	(37)	(2)	%	Consolidated gross profit	$	684		$	717		$	(33)	(5)	%	$	2,070		$	2,300		$	(230)	(10)	%

Gross margin:	Gross margin:																					Gross margin:
Core Illumina	Core Illumina	67.9		%	70.7		%					69.0		%	70.6		%					Core Illumina	64.7		%	67.9		%					64.7		%	69.0		%
GRAIL	GRAIL	*			*							*			*							GRAIL	*			*							*			*
Consolidated gross margin	Consolidated gross margin	64.3		%	69.5		%					65.7		%	70.2		%					Consolidated gross margin	61.1		%	64.3		%					61.2		%	65.7		%

________________

*~~Not meaningful.~~

3432

Table of Contents

*Not meaningful.

The ~~decreases~~decrease in Core Illumina gross margin in Q3 ~~2022~~2023 and YTD ~~2022 were~~2023 was driven primarily by less fixed cost leverage on lower manufacturing volumes, lower instrument margins due to the NovaSeq X launch, which is typical with a new platform introduction until we scale manufacturing and ~~higher freight~~gain operating efficiencies, and unfavorable product mix, as well as increased field services and installation costs, partially offset by ~~favorable product mix. The decrease in YTD 2022 was also driven by increased revenue from a patent litigation settlement in Q2 2021.~~lower freight costs.

GRAIL gross loss ~~for~~in Q3 2023 and Q3 2022 ~~YTD 2022 and Q3 2021~~ and YTD ~~2021, for the period subsequent to the acquisition,~~2023 and YTD 2022 was primarily due to amortization of intangible assets of $33 million and $100 million, ~~and $12 million,~~ respectively.

Operating Expense


Dollars in millions	Dollars in millions	Q3 2022		Q3 2021		Change		% Change		YTD 2022		YTD 2021		Change		% Change		Dollars in millions	Q3 2023		Q3 2022		Change		% Change		YTD 2023		YTD 2022		Change		% Change
Research and development:	Research and development:																	Research and development:
Core Illumina	Core Illumina	$	253	$	212	$	41	19	%	$	740	$	611	$	129	21	%	Core Illumina	$	238	$	253	$	(15)	(6)	%	$	771	$	740	$	31	4	%
GRAIL	GRAIL	74		224		(150)		(67)		245		224		21		9		GRAIL	79		74		5		7		254		245		9		4
Eliminations	Eliminations	(2)		—		(2)		100		(10)		—		(10)		100		Eliminations	(2)		(2)		—		—		(12)		(10)		(2)		20
Consolidated research and development	Consolidated research and development	325		436		(111)		(25)		975		835		140		17		Consolidated research and development	315		325		(10)		(3)		1,013		975		38		4

Selling, general and administrative:	Selling, general and administrative:																	Selling, general and administrative:
Core Illumina	Core Illumina	66		365		(299)		(82)		656		1,152		(496)		(43)		Core Illumina	216		66		150		227		857		656		201		31
GRAIL	GRAIL	81		514		(433)		(84)		210		514		(304)		(59)		GRAIL	87		81		6		7		271		210		61		29
Eliminations	Eliminations	(1)		—		(1)		100		(1)		—		(1)		100		Eliminations	—		(1)		1		(100)		(1)		(1)		—		—
Consolidated selling, general and administrative	Consolidated selling, general and administrative	146		879		(733)		(83)		865		1,666		(801)		(48)		Consolidated selling, general and administrative	303		146		157		108		1,127		865		262		30

Goodwill and intangible impairment:																		Goodwill and intangible impairment:
GRAIL																		GRAIL	821		3,914		(3,093)		(79)		821		3,914		(3,093)		(79)

Legal contingency and settlement:	Legal contingency and settlement:																	Legal contingency and settlement:
Core Illumina	Core Illumina	(11)		—		(11)		100		598		—		598		100		Core Illumina	(1)		(11)		10		(91)		14		598		(584)		(98)

Goodwill impairment:
GRAIL		3,914		—		3,914		100		3,914		—		3,914		100
Total consolidated operating expense	Total consolidated operating expense	$	4,374	$	1,315	$	3,059	233	%	$	6,352	$	2,501	$	3,851	154	%	Total consolidated operating expense	$	1,438	$	4,374	$	(2,936)	(67)	%	$	2,975	$	6,352	$	(3,377)	(53)	%

Core Illumina ~~research~~R&D expense decreased by $15 million, or 6%, in Q3 2023 primarily due to decreases in expenses related to lab supplies, professional services, recruiting, and ~~development~~travel, as we continue to focus on our cost reduction initiatives. Core Illumina R&D expense increased by ~~$41~~$31 million, or ~~19%, in Q3 2022 and by $129 million, or 21%~~4%, in YTD ~~2022~~2023 primarily due to ~~increases~~an increase in ~~headcount,~~compensation related expenses, including performance-based compensation, as we continue to invest in the research and development of new products and enhancements to existing products and $13 million for restructuring activities that commenced in Q2 2023, primarily related to employee separation costs. The increase in YTD 2023 was partially offset by decreases in expenses related to lab supplies, professional services, recruiting, and travel.

GRAIL R&D expense increased by $5 million, or 7%, in Q3 2023 and by $9 million, or 4%, in YTD 2023 primarily due to an increase in headcount and employee related compensation costs, as well as an increase in lab and consumables spend, partially offset by a decrease in ~~performance-based compensation.~~clinical trial costs.

~~GRAIL research and development~~Core Illumina SG&A expense ~~for~~increased by $150 million, or 227%, in Q3 2023 primarily due to a lower gain recognized on our contingent consideration liability in Q3 2023 as compared to Q3 2022 ~~and YTD 2022 consisted primarily~~(recognized a gain of expenses related to headcount, including performance-based compensation, and clinical trials. GRAIL research and development expense for Q3 2021 and YTD 2021, for the period subsequent to the acquisition, consisted primarily of $167 million of share-based compensation expense related to the acceleration of outstanding equity awards as part of the acquisition, as well as other compensation costs related to the acquisition, and expenses related to headcount and clinical trials.

$110

3533

Table of Contents

million and $219 million in Q3 2023 and Q3 2022, respectively, primarily related to the GRAIL CVRs) and $55 million for restructuring activities, primarily related to lease and other asset impairments, partially offset by decreases in professional services and travel. Core Illumina ~~selling, general and administrative~~SG&A expense ~~decreased~~increased by ~~$299~~$201 million, or ~~82%, in Q3 2022 and by $496 million, or 43%~~31%, in YTD ~~2022~~2023 primarily due to ~~the fair value changes~~a lower gain recognized on our contingent consideration liability in YTD 2023 as compared to YTD 2022 (recognized a net gain of ~~$218~~$82 million and $230 million in ~~Q3 2022~~YTD 2023 and YTD 2022, respectively, ~~related~~ primarily ~~to our GRAIL contingent consideration liability, and a decrease in expenses~~ related to ~~our acquisition~~the GRAIL CVRs), $74 million for restructuring activities that commenced in Q2 2023, primarily related to lease and other asset impairments and employee separation costs, and costs related to the proxy contest of $29 million, partially offset by decreases in professional services and recruiting costs.

GRAIL ~~including $35~~SG&A expense increased by $6 million, ~~and $245 million in Continuation Payments made to GRAIL~~or 7%, in Q3 ~~2021~~2023 and by $61 million, or 29%, in YTD ~~2021, respectively.~~2023 primarily due to an increase in headcount and employee related compensation costs. The ~~decreases~~increase in ~~Q3 2022 and~~ YTD ~~2022 were~~2023 was also due to ~~decreases in performance-based compensation, partially offset by~~ increases in ~~headcount~~professional services and ~~travel expenses.~~marketing related spend.

GRAIL ~~selling, general~~goodwill and ~~administrative expense~~intangible impairment for Q3 2023 and YTD 2023 consisted of goodwill impairment of $712 million and IPR&D intangible asset impairment of $109 million as a result of performing an interim impairment test due to the identification of a triggering event in Q3 2023. See note “6. Supplemental Balance Sheet Details” for additional details. GRAIL goodwill and intangible impairment for Q3 2022 and YTD 2022 consisted ~~primarily~~ of ~~expenses~~a goodwill impairment charge of $3,914 million as a result of performing an interim impairment test in Q3 2022.

Core Illumina legal contingency and settlement in Q3 2023 consisted of a gain on a patent litigation settlement. Core Illumina legal contingency and settlement in YTD 2023 also consisted of an adjustment to our previously recorded accrual for the fine imposed by the European Commission in July 2023 (refer to note “7. Legal Proceedings” for additional details) and a loss related to headcount, including performance-based compensation, and professional services. GRAIL selling, general and administrative expense for Q3 2021 and YTD 2021, for the period subsequent to the acquisition, consisted primarily of $448 million of share-based compensation expense related to the acceleration of outstanding equity awards as part of the acquisition, as well as other compensation and transaction costs related to the acquisition, and expenses related to headcount.

a patent litigation settlement in Q1 2023. Core Illumina legal contingency and settlement for Q3 2022 consisted of a gain of $11 million as a result of releasing $6 million of a previously recorded litigation accrual and $5 million of gain contingency recognized in Q3 2022 related to the settlement of our litigation with BGI. Core Illumina legal contingency and settlement for YTD 2022 consisted of an accrual of $453 million for the ~~potential~~ fine that the European Commission ~~may impose of up to 10% of our consolidated annual revenues~~imposed and a net loss of $145 million related to the settlement of our litigation with BGI. ~~See note “7. Legal Proceedings” for additional details.~~

GRAIL goodwill impairment for Q3 2022 and YTD 2022 consisted of a goodwill impairment charge of $3,914 million as a result of performing an interim impairment test due to the identification of certain triggering events in Q3 2022. See note “~~6. Supplemental Balance Sheet Details” for additional details.~~

~~Other Income (Expense)~~

Dollars in millions Q3 2022 Q3 2021 Change % Change YTD 2022 YTD 2021 Change % Change
Interest income $ 3 $ — $ 3 100 % $ 4 $ — $ 4 100 %
Interest expense (6) (14) 8 (57) (17) (48) 31 (65)
Other (expense) income, net (12) 979 (991) (101) (103) 1,010 (1,113) (110)
Total other (expense) income, net $ (15) $ 965 $ (980) (102) % $ (116) $ 962 $ (1,078) (112) %

~~Total other (expense) income, net relates primarily to the Core Illumina segment.~~

~~Interest expense in Q3 2022 and YTD 2022 consisted primarily of accrued interest on our Term Notes. The decreases in Q3 2022 and YTD 2022 were primarily due to the~~ ~~accretion of the original debt discount on our c~~onvertible senior notes, prior to the adoption of ASU 2020-06. The decrease in YTD 2022 was also due to the recognition of interest expense in YTD 2021 associated with the amortization of debt issuance costs related to the termination of our Bridge Facility in Q1 2021. The decreases in other (expense) income, net in Q3 2022 and YTD 2022 were primarily due to the gain of $900 million from our previously held investment in GRAIL, which was recorded in Q3 2021 as part of the acquisition, as well as higher unrealized losses on our marketable equity securities and Helix contingent value right in Q3 2022 and YTD 2022. The decrease in other (expense) income, net in YTD 2022 was also due to a $26 million gain recorded on our derivative assets related to the terminated PacBio acquisition in Q1 2021.

3634

Table of Contents

Other Income (Expense)


Dollars in millions	Q3 2023		Q3 2022		Change		% Change		YTD 2023		YTD 2022		Change		% Change

Interest income	$	13	$	3	$	10	333	%	$	47	$	4	$	43	1,075	%




Interest expense	(19)		(6)		(13)		217		(59)		(17)		(42)		247




Other expense, net	(22)		(12)		(10)		83		(33)		(103)		70		(68)



Total other expense, net	$	(28)	$	(15)	$	(13)	87	%	$	(45)	$	(116)	$	71	(61)	%

Total other expense, net primarily relates to the Core Illumina segment.

Interest income consisted primarily of interest on our money market funds, which benefited from higher yields in Q3 2023 and YTD 2023 due to rising interest rates. Interest expense consisted primarily of interest on our Term Notes and increased in Q3 2023 and YTD 2023 due to the issuance of our 2025 and 2027 Term Notes in December 2022. The fluctuation in other expense, net in Q3 2023 was primarily due to higher net losses recognized on our strategic investments as compared to Q3 2022 and a net unrealized foreign currency loss related to the fine imposed by the European Commission, partially offset by a favorable impact related to our Helix contingent value right. The fluctuation in other expense, net in YTD 2023 was primarily due to lower net losses recognized on our strategic investments as compared to YTD 2022 ($39 million and $79 million in YTD 2023 and YTD 2022, respectively) and favorable impacts related to our Helix contingent value right and deferred compensation plan assets, partially offset by a net unrealized foreign currency loss related to the fine imposed by the European Commission.

(Benefit) Provision for Income Taxes

Dollars in millions Q3 2022 Q3 2021 Change % Change YTD 2022 YTD 2021 Change % Change
(Loss) income before income taxes $ (3,672) $ 420 $ (4,092) (974) % $ (4,168) $ 798 $ (4,966) (622) %
Provision for income taxes 144 103 41 40 97 148 (51) (34)
Net (loss) income $ (3,816) $ 317 $ (4,133) (1,304) % $ (4,265) $ 650 $ (4,915) (756) %
Effective tax rate (4.0) % 24.7 % (2.3) % 18.6 %


Dollars in millions	Q3 2023			Q3 2022			Change		% Change		YTD 2023			YTD 2022			Change		% Change
Loss before income taxes	$	(782)		$	(3,672)		$	2,890	(79)	%	$	(950)		$	(4,168)		$	3,218	(77)	%
(Benefit) provision for income taxes	(28)			144			(172)		(119)		36			97			(61)		(63)
Net loss	$	(754)		$	(3,816)		$	3,062	(80)	%	$	(986)		$	(4,265)		$	3,279	(77)	%
Effective tax rate	3.6		%	(4.0)		%					(3.8)		%	(2.3)		%

Our effective tax rate was 3.6% and (3.8)% in Q3 2023 and YTD 2023, respectively, compared to (4.0)% and (2.3)% in Q3 2022 ~~compared to 24.7% in Q3 2021.~~and YTD 2022, respectively. The variance from the U.S. federal statutory tax rate of 21% for Q3 2023 and YTD 2023 was primarily because of the ~~$822~~$149 million income tax expense impact from the impairment of goodwill, which is nondeductible for tax purposes, the ~~$30~~$20 million and $84 million income tax expense impact of capitalizing research and development expenses for tax purposes, respectively, and the $38 million and $63 million income tax expense impact of GRAIL pre-acquisition net operating losses on GILTI and the utilization of U.S. foreign tax credits, respectively. The income tax expense in Q3 2023 and YTD 2023 were also favorably impacted by the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore.

The income tax benefits in Q3 2022 and YTD 2022 had an effective tax rate that was lower than the U.S. federal statutory tax rate of 21% primarily because of the $822 million income tax expense impact from the impairment of goodwill, which is nondeductible for tax purposes, the $64 million and $91 million income tax expense impact of capitalizing research and development expenses, respectively, and the $30 million and $60 million income tax expense impact of GRAIL pre-acquisition net operating losses on GILTI and the utilization of the U.S. foreign tax credits, respectively. The YTD 2022 income tax benefit was also impacted by the $95 million income tax expense impact from the European Commission fine related to the GRAIL acquisition, which was accrued in Q2 2022 and is nondeductible for tax purposes beginning in 2022, in accordance with the 2017 Tax Cuts and Jobs Act. If the capitalization requirement is not repealed or modified, potentially retroactively to the beginning of 2022, our provision for income taxes will continue to be negatively impacted and our future cashpurposes. Our effective tax ~~payments will increase by approximately $163 million due to the impact of capitalizing research and development expenses in 2022. The tax expense~~rate in Q3 2022 ~~was~~and YTD 2022 were also favorably impacted by the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore and the United Kingdom.

~~In Q3 2021,~~

Table of Contents

Historically, we calculated the variance from the U.S. federal statutory tax rate of 21% was primarily attributable to discrete tax benefits related to GRAIL Continuation Payments and the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore and the United Kingdom.

~~Our~~provision/(benefit) for income taxes for interim periods utilizing an estimated annual effective tax rate ~~was (2.3)%~~applied to the income/(loss) for the reporting period, except in ~~YTD 2022 compared to 18.6% in YTD 2021. The variance from the U.S. federal statutory~~Q2 2023 when a year-to-date effective tax rate ~~of 21%~~method was ~~primarily because~~utilized.We determined the estimated annual effective tax rate method would provide a more reliable estimate of the ~~$822 million~~provision for income taxes for Q3 2023 and YTD 2023, since minor changes in the estimated income/(loss) before income taxes would not result in significant changes in the estimated annual effective tax impact from the impairment of goodwill and the $95 million tax impact from the potential European Commission fine related to the GRAIL acquisition, both of which are nondeductible for tax purposes, the $91 million tax impact of capitalizing research and development expenses for tax purposes beginning in 2022, in accordance with the 2017 Tax Cuts and Jobs Act, and the $60 million tax impact of GRAIL pre-acquisition net operating losses on GILTI and the utilization of the U.S. foreign tax credits. The tax expense in YTD 2022 was also favorably impacted by the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore and the United Kingdom.

In YTD 2021, the variance from the U.S. federal statutory tax rate of 21% was primarily attributable to discrete tax benefits related to GRAIL Continuation Payments and the mix of earnings in jurisdictions with lower statutory tax rates than the U.S. federal statutory tax rate, such as in Singapore and the United Kingdom. This was partially offset by tax expense on certain foreign subsidiary earnings that are no longer indefinitely reinvested.rate.

Our future effective tax rate may vary from the U.S. federal statutory tax rate due to the mix of earnings in tax jurisdictions with different statutory tax rates and the other factors discussed in the risk factor “We are subject to risks related to taxation in multiple jurisdictions” described in “Risk Factors” within the Business & Market Information section of our Annual Report on Form 10-K for the fiscal year ended January ~~2, 2022.~~1, 2023.

LIQUIDITY AND CAPITAL RESOURCES

AtAs of October ~~2, 2022,~~1, 2023, we had approximately ~~$1.0 billion~~$927 million in cash and cash equivalents, of which approximately ~~$537~~$499 million was held by our foreign subsidiaries. Cash and cash equivalents decreased by ~~$232~~$1,084 million from January ~~2, 2022,~~1, 2023 due primarily to the repayment of our 2023 Term Notes in Q1 2023 of $500 million, the repayment of our 2023 Convertible Notes in Q3 2023 of $750 million, and other factors described in the “Cash Flow Summary” below. Our primary source of liquidity, other than our holdings of cash, cash equivalents, and investments, has been cash flows from operations and, from time to time, issuances of debt. Our ability to generate cash from operations provides us with the financial flexibility we need to meet operating, investing, and financing needs.

~~Table of Contents~~

Historically, we have liquidated our short-term investments and/or issued debt ~~convertible debt, and equity securities~~ to finance our business needs as a supplement to cash provided by operating activities. As of October ~~2, 2022,~~1, 2023, we had ~~$41~~$6 million in short-term investments comprised of marketable equity securities.

On July 12, 2023, as a result of our decision to proceed with the completion of our acquisition of GRAIL during the pendency of the European Commission’s review, the European Commission imposed a €432 million fine on us, representing the maximum fine of 10% of our consolidated annual revenues for fiscal year 2022. As of October 2,1, 2023, we accrued $458 million, including related foreign currency gains, included in accrued liabilities. We provided guarantees in October 2023 to satisfy the obligation in lieu of cash payment while we appeal the European Commission’s jurisdictional decision and fine decision. The fine is accruing interest at a rate of 5.5% per annum, beginning in October 2023, while it is outstanding. Refer to note “7. Legal Proceedings” for additional details.

In March 2021, we issued term notes due 2023 with an aggregate principal amount of $500 million and term notes due 2031 with an aggregate principal amount of $500 million. The 2023 Term Notes matured and were repaid in cash on March 23, 2023. The 2031 Term Notes, which mature on March 23, 2031, accrue interest at a rate of 2.550% per annum, payable semi-annually in March and September of each year. We may redeem for cash all or any portion of the 2031 Term Notes, at our option, at any time prior to maturity.

Our convertible senior notes, with an aggregate principal amount of $750 million, matured on August 15, 2023, at which time the principal was repaid in cash. We did not issue any shares of common stock.

In December 2022, we issued term notes due 2025 with an aggregate principal amount of $500 million and term notes due 2027 with an aggregate principal amount of $500 million. The 2025 Term Notes, which mature on December 12, 2025, and the 2027 Term Notes, which mature on December 13, 2027, accrue interest at a rate of 5.800% and 5.750% per annum, respectively, payable semi-annually in June and December of each year. We may redeem for cash all or any portion of the 2025 or 2027 Term Notes, at our option, at any time prior to maturity.

On January 4, 2023, we obtained a new Credit Facility, which provides us with a $750 million senior unsecured five year revolving credit facility, including a $40 million sublimit for swingline borrowings and a $50 million sublimit for letters of credit. The Credit Facility matures, and all amounts outstanding thereunder become due and payable in full, on January 4, 2028, subject to two one-year extensions at our option and the consent of the extending lenders and certain other conditions. As of October 1, 2023, there were no borrowings outstanding under the Credit Facility; however, we may draw upon the facility in the future to manage cash flow or for other corporate purposes, including in connection with the payment of the €432 million European Commission fine. We provided guarantees in October 2023 to satisfy the obligation in lieu of cash payment while we appeal the European Commission’s jurisdictional decision and fine decision.

Table of Contents

As of October 1, 2023, the fair value of our contingent consideration liability related to our acquisition of GRAIL was ~~$387 million.~~$330 million, of which $329 million was included in other long-term liabilities. The contingent value rights issued as part of the acquisition entitle the holders to receive future cash payments on a quarterly basis (Covered Revenue Payments) representing a pro rata portion of certain GRAIL-related revenues (Covered Revenues) each year for a 12-year period. This will reflect a 2.5% payment right to the first $1 billion of revenue each year for 12 years. Revenue above $1 billion each year will be subject to a 9% contingent payment right during this same period. We expect Covered Revenues for ~~Q4 2021, Q1 2022,~~Q3 2023 to be approximately $21 million and Q2 2022 were $32 million in aggregate, driven primarily by sales of GRAIL’s Galleri test. Corresponding Covered Revenue Payments in YTD 2022 were approximately $297,000; however, pursuant to the Contingent Value Rights Agreement, a portion of the Covered Revenue Payments were applied to reimburse us for ~~certain expenses. We expect~~related Covered Revenue Payments to total approximately ~~$99,000~~$194,000 in Q4 ~~2022 due~~2023. In YTD 2023, we paid $609,000 in aggregate Covered Revenue Payments related to Covered Revenues for Q3Q4 2022, Q1 2023, and Q2 2023 of ~~approximately $10 million.~~$65 million in aggregate.

We ~~continued to~~ grant ~~GRAIL employees~~ cash incentive equity awards to GRAIL employees that generally have terms of four years and vest in ~~YTD 2022.~~equal annual installments. As of October ~~2, 2022,~~1, 2023, the aggregate cash value of awards outstanding and unvested was ~~$226~~$308 million, and we accrued an estimated liability of ~~$24~~$42 million, included in accrued liabilities. In addition, we have an outstanding performance-based award for which vesting is based on GRAIL’s future revenues. The award has an aggregate potential value of up to $78 million, which is expected to be settled in cash, and expires, to the extent unvested, in August 2030. As of October ~~2, 2022,~~1, 2023, it was not probable that the performance conditions associated with the award will be achieved.

As a result of our decision to proceed with the completion of our acquisition of GRAIL during the pendency of the European Commission’s review, the European Commission will likely seek to impose a fine on us. In YTD 2022, we accrued $453 million, included in accrued liabilities, representing 10% of our consolidated annual revenues for fiscal year 2021, as further disclosed in note “~~7. Legal Proceedings~~.”

On March 23, 2021, we issued term notes due 2023 with an aggregate principal amount of $500 million and term notes due 2031 with an aggregate principal amount of $500 million. The 2023 Term Notes and the 2031 Term Notes accrue interest at a rate of 0.550% and 2.550% per annum, respectively, payable semi-annually on March 23 and September 23 of each year. The 2023 Term Notes, which are classified as short-term, mature on March 23, 2023 and the 2031 Term Notes mature on March 23, 2031. We may redeem for cash all or any portion of the Term Notes, at our option, at any time prior to maturity. Our convertible senior notes, with an aggregate principal amount of $750 million, which are classified as short-term and due on August 15, 2023, were not convertible as of October 2, 2022. The holders may convert their notes on or after May 15, 2023 until August 11, 2023.

On March 8, 2021, we obtained a Credit Facility, which provides us with a $750 million senior unsecured five-year revolving credit facility, including a $40 million sublimit for swingline borrowings and a $50 million sublimit for letters of credit. The Credit Facility matures, and all amounts outstanding thereunder become due and payable in full, on March 8, 2026, subject to two one-year extensions at our option and the consent of the extending lenders and certain other conditions. As of October 2, 2022, there were no borrowings outstanding under the Credit Facility.

We had ~~$11~~$5 million and up to ~~$101~~$74 million, respectively, remaining in our capital commitments to two venture capital investment funds as of October ~~2, 2022~~1, 2023 that are callable through April 2026 and July 2029, respectively.

Authorizations to repurchase $15 million of our common stock remained available as of October ~~2, 2022~~1, 2023 under the $750 million share repurchase program authorized by our Board of Directors on February 5, 2020. The repurchases may be completed under a 10b5-1 plan or at management’s discretion. We do not intend to make any share repurchases during fiscal year ~~2022.~~2023.

We anticipate that our current cash, cash equivalents, and short-term investments, together with cash provided by operating activities and available borrowing capacity under the Credit Facility, are sufficient to fund our near-term capital and operating needs for at least the next 12 months. Operating needs include the planned costs to operate our business, including amounts required to fund working capital and capital expenditures. Our primary short-term needs for capital, which are subject to change, include:

•support of commercialization efforts related to our current and future products;

~~Table of Contents~~

•acquisitions of equipment and other fixed assets for use in our current and future manufacturing and research and development facilities;

•the continued advancement of research and development efforts;

•the payment of the European Commission fine related to our acquisition of GRAIL;

•the requirement to ensure that GRAIL has access to sufficient funds, at the time of a divestment, to cover at least 2.5 years of operations according to its latest long-range plan per the EC Divestment Decision;

•potential strategic acquisitions and investments;

•repayment of debt obligations; and

•the expansion needs of our facilities, including costs of leasing and building out additional facilities.

We expect that our revenue and the resulting operating income, as well as the status of each of our new product development programs, will significantly impact our cash management decisions.

Our future capital requirements and the adequacy of our available funds will depend on many factors, including:

•our ability to successfully commercialize and further develop our technologies and create innovative products in our markets;

•scientific progress in our research and development programs and the magnitude of those programs;

Table of Contents

•competing technological and market developments; and

•the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings.

Cash Flow Summary


In millions	In millions	YTD 2022		YTD 2021		In millions	YTD 2023		YTD 2022
Net cash provided by operating activities	Net cash provided by operating activities	$	245	$	263	Net cash provided by operating activities	$	254	$	245
Net cash used in investing activities	Net cash used in investing activities	(489)		(1,069)		Net cash used in investing activities	(146)		(489)
Net cash provided by financing activities		44		78
Net cash (used in) provided by financing activities						Net cash (used in) provided by financing activities	(1,183)		44
Effect of exchange rate changes on cash and cash equivalents	Effect of exchange rate changes on cash and cash equivalents	(32)		(2)		Effect of exchange rate changes on cash and cash equivalents	(9)		(32)
Net decrease in cash and cash equivalents	Net decrease in cash and cash equivalents	$	(232)	$	(730)	Net decrease in cash and cash equivalents	$	(1,084)	$	(232)

Operating Activities

Net cash provided by operating activities in YTD ~~2022~~2023 primarily consisted of a net loss of $986 million, plus net adjustments of ~~$4,292~~$1,408 million, ~~and~~less net changes in operating assets and liabilities of ~~$218 million, less net loss of $4,265~~$168 million. The primary adjustments to net loss included goodwill and intangible (IPR&D) impairment of ~~$3,914~~$821 million, depreciation and amortization expense of ~~$288~~$323 million, share-based compensation expense of ~~$266~~$286 million, property and equipment and right-of-use asset impairment of $56 million, net losses on strategic investments of ~~$79~~$39 million and an unrealized loss on foreign exchange translation of $21 million, partially offset by ~~a gain recorded on our~~change in fair value of contingent consideration ~~liability~~liabilities of ~~$230~~$82 million and deferred income taxes of ~~$40~~$42 million. Cash flow impact from changes in net operating assets and liabilities were primarily driven by ~~an increase~~increases in ~~accrued liabilities due to a legal contingency, partially offset by an increase in~~ inventory and accounts receivable and decreases in accounts payable and ~~other long-term~~accrued liabilities.

Investing Activities

Net cash used in investing activities totaled ~~$489~~$146 million in YTD ~~2022.~~2023. We invested ~~$198~~$144 million in capital expenditures, primarily associated with our investment in facilities, ~~paid $180~~and $19 million ~~for an intangible asset related to our settlement with BGI, paid $85 million for an acquisition, and~~was used ~~$26 million~~ for purchases of strategic ~~investments.~~investments, partially offset by sales of our strategic investments of $18 million.

Financing Activities

Net cash ~~provided by~~used in financing activities totaled ~~$44~~$1,183 million in YTD ~~2022.~~2023. We used $500 million to repay our 2023 Term Notes in Q1 2023, used $750 million to repay our 2023 Convertible Notes in Q3 2023, and used $14 million to pay taxes related to net share settlement of equity awards, partially offset by $67 million received ~~$63 million~~ in proceeds from the sale of shares under our employee stock purchase ~~plan, partially offset by $19 million used to pay taxes related to net share settlement of equity awards.~~plan.

~~Table of Contents~~

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

In preparing our condensed consolidated financial statements, we make estimates, assumptions and judgments that can have a significant impact on our net revenue, operating income (loss) and net income (loss), as well as on the value of certain assets and liabilities on our balance sheet. We believe that the estimates, assumptions and judgments involved in the accounting policies described in “Critical Accounting Policies and Estimates” within the Management’s Discussion & Analysis section of our Annual Report on Form 10-K for the fiscal year ended January ~~2, 2022~~1, 2023 have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. Though the ~~impact of the~~ COVID-19 pandemic, ~~to our business~~the armed conflict between Russia and ~~operating results presents~~Ukraine, and macroeconomic factors such as inflation, exchange rates and concerns about an economic downturn present additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. There were no material changes to our critical accounting policies and estimates during YTD ~~2022. For details regarding~~2023, with the ~~interim impairment assessments performed for goodwill and intangible assets, see footnote~~exception of income taxes as disclosed in note “~~6. Supplemental Balance Sheet Details~~1. Organization and Significant Accounting Policies.”

Table of Contents

RECENT ACCOUNTING PRONOUNCEMENTS

For a summary of recent accounting pronouncements applicable to our condensed consolidated financial statements, see note “1. Organization and Significant Accounting Policies” within the Condensed Consolidated Financial Statements section of this report, which is incorporated herein by reference.

QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK

There were no substantial changes to our market risks in YTD ~~2022,~~2023, when compared to the disclosures in “Quantitative and Qualitative Disclosures about Market Risk” within the Management’s Discussion & Analysis section of our Annual Report on Form 10-K for the fiscal year ended January ~~2, 2022.~~1, 2023.


OTHER KEY INFORMATION

CONTROLS AND PROCEDURES

We design our internal controls to provide reasonable assurance that (1) our transactions are properly authorized; (2) our assets are safeguarded against unauthorized or improper use; and (3) our transactions are properly recorded and reported in conformity with U.S. generally accepted accounting principles. We also maintain internal controls and procedures to ensure that we comply with applicable laws and our established financial policies.

During the third quarter of 2023, we continued to monitor and evaluate the design and operating effectiveness of key controls. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that materially affected or are reasonably likely to materially affect internal control over financial reporting.

Based on management’s evaluation (under the supervision and with the participation of our chief executive officer (CEO) and chief financial officer (CFO)), as of the end of the period covered by this report, our CEO and CFO concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), are effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

During Q3 2022, we continued to monitor and evaluate the design and operating effectiveness of key controls, including the impact of the COVID-19 pandemic on our internal control environment. There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that materially affected or are reasonably likely to materially affect internal control over financial reporting.

LEGAL PROCEEDINGS

See discussion of legal proceedings in note “7. Legal Proceedings” in the Condensed Consolidated Financial Statements section of this report, which is incorporated herein by reference.

4039

Table of Contents

RISK FACTORS

Our business is subject to various risks, including those described in “Risk Factors” within the Business & Market Information ~~Section~~section of our Annual Report on Form 10-K for the fiscal year ended January ~~2, 2022, and~~1, 2023, the “Other Key Information” section of our Quarterly Report on Form 10-Q for the period ended April ~~3, 2022,~~2, 2023 and on Form 10-Q for the period ended July 2, 2023, which we strongly encourage you to review. In addition to the risk factors disclosed in our ~~Form~~ ~~10-K~~F o r m 1 0 -K,Form 10-Q for Q1 2023 and Form 10-Q for Q2 2023, the issues raised in the following risk ~~factors~~factor could adversely affect our operating results and stock price:

Our acquisition ~~(the Acquisition)~~ of GRAIL remains subject to ongoing legal and regulatory proceedings in the United States and in the European Union. Adverse decisions by the EU ~~General Court,~~and/or U.S. courts, the European Commission, the FTC and/or other governmental or regulatory authorities, that have been issued in the past or may be issued in the future, and/or other adverse consequences resulting from our decision to proceed with the completion of the acquisition, ~~could result~~have resulted in significant financial penalties, operational restrictions and increased costs, and could result in similar additional future consequences or further result in loss of revenues, implicate our existing contractual arrangements or require us to divest all or a portion of the assets or equity interests of GRAIL on terms that are materially worse than the terms on which we acquired GRAIL, any or all of which, individually or in the aggregate, could have a material adverse effect on our business, financial condition and results of operation.

As previously disclosed, on March 30, 2021, the ~~U.S. Federal Trade Commission (the FTC)~~FTC filed an administrative complaint alleging that our acquisition of GRAIL (the Acquisition) would violate Section 7 of the Clayton Act, as amended, 15 U.S.C. § 18. ~~We filed an answer to the FTC’s complaint in the administrative court on April 13, 2021, and the administrative trial commenced on August 24, 2021.~~ On September 1, 2022, the administrative law judge (the ALJ) ruled in favor of Illumina and found that the acquisition of GRAIL did not violate Section 7 of the Clayton Act. In the decision, the ALJ found that the FTC’s complaint counsel had failed to prove its prima facie case that Illumina’s acquisition of GRAIL would result in harm to competition in a putative market for multi-cancer early detection (MCED) tests. The FTC’s complaint counsel appealed the ALJ’s decision to the full FTC on September 2, ~~2022,~~2022. On March 31, 2023, the FTC issued an opinion and ~~on October 4, 2022,~~order (the FTC Order) requiring Illumina to divest GRAIL, reversing the ~~FTC’s complaint counsel~~ALJ’s ruling. On April 5, 2023, Illumina filed a petition for review of the FTC Order in the U.S. Court of Appeals for the Fifth Circuit. On April 24, 2023, the FTC granted a motion staying in its entirety the FTC Order pending resolution of Illumina’s Fifth Circuit appeal. Illumina submitted its opening appeal brief. on June 5, 2023. The appeal was fully briefed as of August 16, 2023 and oral argument occurred on September 12, 2023. We intend to continue to vigorously defend against the FTC action.

As previously disclosed, on April 19, 2021, the European Commission accepted a request for referral of the Acquisition (the Referral) for European Union merger review under Article 22(1) of Council Regulation (EC) No 139/2004 (the EU Merger Regulation), which had been submitted by a Member State of the European Union. The European Commission had previously notified us asserting that as a result of the Referral, pursuant to Article 22(4) of the EU Merger Regulation, we were prohibited from implementing the Acquisition (i) until the European Commission clears the Acquisition under the EU Merger Regulation or (ii) until the European Commission refuses the Referral, and therefore the European Commission’s acceptance of the Referral continued the purported standstill on the completion of the Acquisition until such time as the European Commission completes its review and approves the Acquisition. On April 29, 2021, we filed an action in the General Court of the European Union (the EU General Court) asking for annulment of the European Commission’s decision asserting jurisdiction to review the Acquisition under Article 22 of the EU Merger Regulation, as the Acquisition does not meet the jurisdictional criteria under the EU Merger Regulation or under the national merger control laws of any Member State of the European Union. On December 16, 2021, the EU General Court held a hearing regarding the European Commission’s assertion of jurisdiction. On July 13, 2022, the EU General Court ruled that the European Commission has jurisdiction to review the Acquisition under the EU Merger Regulation. On September 22, 2022, we filed an appeal in the Court of Justice of the European Union asking for annulment of the EU General Court’s decision.

As previously disclosed, on October 29, 2021, the European Commission adopted an order imposing interim measures (the Initial Interim Measures Order), which was renewed on October 28, 2022 (subject to certain operational modifications and also expressly prohibits Illumina from selling, transferring, encumbering or otherwise disposing of GRAIL or any of GRAIL’s assets), provided that (i) we ensure that Illumina and GRAIL will continue to operate as independent legal entities that transact at arms’ length, no integration activity will take place, the day-to-day operation of GRAIL will remain the sole responsibility of GRAIL’s management and our management will have no involvement in or influence over GRAIL, (ii) we take certain supportive measures to preserve GRAIL’s viability, marketability and competitiveness, including with respect to the provision of resources to GRAIL and the retention and/or replacement of key personnel of GRAIL, (iii) subject to limited exceptions, we implement all necessary measures to ensure that Illumina does not obtain any confidential information relating to GRAIL during the hold separate period and vice versa and (iv) we appoint an independent firm as monitoring trustee to monitor our compliance with the Initial Interim Measures Order. An independent monitoring trustee has been appointed. As the Initial Interim Measures Order was set to expire on November 3, 2022, the European Commission adopted a new order imposing interim measures (the New Interim Measures Order) on October 28, 2022. The New Interim Measures Order renews, subject to certain operational modifications, Illumina’s obligations under the Initial Interim

~~Table of Contents~~

~~Measures Order (as described above).~~ Such hold separate arrangement, and our obligations pursuant thereto, have imposed implementation and administrative processes and additional legal, financial advisory, regulatory and other professional services costs, which have been burdensome to implement and administer, and which we expect to continue for the duration of the hold separate ~~arrangement.~~arrangement (in the form of transitional measures imposed on Illumina pursuant to a decision adopted by the European Commission on October 12, 2023 (the EC Divestment Decision), which replaced the New Interim Measures Order). Such burdens and additional costs, independently or together with additional burdens, costs and/or liabilities arising from such arrangement, may result in loss of revenue and other adverse effects on our business, financial condition and results of operations and have an adverse impact on our ability to achieve the anticipated benefits of the ~~Acquisition. Further,~~Acquisition, as further explained below. Moreover, our failure to comply with the terms of the ~~New Interim Measures Order~~EC

Table of Contents

Divestment Decision may result in the European Commission seeking to impose fines or other penalties on us. On ~~December 1, 2021,~~January 10, 2023, we filed an action with the EU General Court asking for annulment of the ~~Initial~~New Interim Measures Order. ~~The hearing of~~On January 20, 2023, the European Commission requested that ~~application has been~~these proceedings be stayed pending our appeal ofon jurisdiction.

We submitted a filing indicating that we had no objections to the ~~judgment of~~European Commission’s request, and the EU General Court ~~regarding~~stayed the ~~European Commission’s assertion of jurisdiction.~~proceedings on February 21, 2023.

On September 6, 2022, the European Commission announced that it had completed its Phase II review of the Acquisition and adopted a final decision (the Prohibition Decision), which found that, in its view, our acquisition of GRAIL was incompatible with the internal market in Europe because it results in a significant impediment to effective competition. ~~We believe that public statements made by~~On November 17, 2022, we filed an action with the EU General Court asking for annulment of the Prohibition Decision. On October 12, 2023, the European Commission ~~in connection with~~adopted the Prohibition Decision indicate that a subsequent decision is likely to be adopted by the European Commission that will order us to divest GRAIL (the EC Divestment Decision). Neither the Prohibition Decision nor such public statements indicate when any such EC Divestment Decision ~~may be adopted.~~requiring us to (among other things) divest GRAIL and imposing the transitional measures. We intend to appeal the ~~Prohibition Decision to the EU General Court by the applicable deadline. We also intend to appeal any~~ EC Divestment ~~Decision (if and when adopted by the European Commission) and, if necessary, to seek interim relief suspending the divestment of GRAIL until the final determination of these appeals.~~Decision.

The Prohibition Decision, ~~and~~ the EC Divestment Decision, and any order or decision by the FTC or any other governmental or regulatory authority pursuant to which Illumina is required to divest GRAIL (an FTC Divestment Decision), if implemented once final and non-appealable or during the pendency of the applicable appeals proceedings, and our obligations pursuant thereto, ~~will~~have imposed in the past and may impose in the future significant costs and additional liabilities on us, including significant legal, financial advisory, regulatory and other professional services fees and additional expenses, and may result in loss of revenue and other adverse effects on our business, financial condition and results of operations. Such adverse effects could include being required to divest GRAIL on terms that are materially worse than the terms on which we acquired GRAIL. Furthermore, we may not be able to direct the timing, structure or financial terms of such divestment, which could result in negative financial or tax consequences. For example, we are unlikely to be able to, in a sale of GRAIL, effect such sale in a non-taxable transaction and so would incur significant tax liabilities attributable to the recognition of taxable gain equal to the difference between (i) the fair market value of any consideration received and (ii) our tax basis in GRAIL (which tax basis is currently estimated to be between zero and $500 ~~million~~million). In addition, any such divestment will likely implicate certain provisions in our third-party contracts and ~~$1 billion).~~other agreements, including our obligations with respect to the contingent value rights (the CVRs) issued by us as part of the Acquisition. We may be unable to fully discharge our obligations with respect to the CVRs in connection with any such divestiture, and/or such divestiture may result in a change in obligor on the CVRs. Moreover, the business of GRAIL may be adversely affected by any such divestment, which could adversely affect the market value of the CVRs. The EC Divestment Decision requires us to ensure that GRAIL has access to sufficient funds to cover at least 2.5 years of operations according to its latest long-range plan.

Furthermore, even if an order or decision by the European Commission, General Court of EU, FTC or any other governmental or regulatory authority, approves the Acquisition, the delay in the approval or/and the imposition of conditions not part of the Acquisition agreement, could adversely affect the synergies and benefits we anticipate from the integration of GRAIL in our operations and may result in loss of revenue and other adverse effects on our business, financial condition and results of operations.

The Initial Interim Measures Order, the New Interim Measures Order, the Prohibition Decision, and ~~the implementation of~~ the EC Divestment Decision, or an FTC Divestment Decision or any other order or decision by any other governmental or regulatory authority, if implemented once final and non-appealable or during the pendency of the applicable appeals proceedings, have in the past and could may also in the future divert management’s attention and company resources away from existing operations and other opportunities that may have been beneficial to us, any or all of which, individually or in the aggregate, could have a material adverse effect on our business, financial condition and results of operation. We have experienced and might continue to experience negative impacts on our stock price. We cannot predict what other adverse consequences to, among other things, our reputation, our relationships with governmental or regulatory authorities, or our ability to successfully complete future transactions, our ability to attract, retain and motivate customers, key personnel and those with whom we conduct business may result.

~~Additionally, on~~On July ~~19, 2022,~~12, 2023, the European Commission ~~issued~~adopted a ~~Statement of Objections alleging~~final decision finding that we breached the EU Merger Regulation by, ~~completing~~in its view, acquiring the ~~Acquisition. We believe that~~possibility to exert decisive influence over GRAIL and exerting such influence during the pendency of the European Commission’s review (the Article 14(2)(b) Decision). The European Commission ~~will likely seek to impose~~therefore imposed a fine on us pursuant to Article 14(2)(b) of the EU Merger Regulation of ~~up to~~

Table of Contents

approximately €432 million, representing the maximum fine of 10% of our consolidated annual revenues ~~(the Article 14(2)(b) Fine).~~for fiscal year 2022. We provided guarantees in October 2023 to satisfy the obligation in lieu of cash payment while we appeal the European Commission’s jurisdictional decision and fine decision. As of October 1, 2023, we accrued $458 million, including related foreign currency gains, included in accrued liabilities. In addition, the European Commission, the FTC and/or other governmental or regulatory authorities may seek to impose other fines, penalties, remedies or restrictions. ~~We intend to vigorously defend against any such fines, penalties, remedies or restrictions, but we cannot predict the scope or severity thereof or the outcome of any related proceedings.~~ We also cannot predict what other adverse consequences to, among other things, our reputation, our relationships with governmental or regulatory authorities or our ability to successfully complete future acquisitions and/or divestitures may result from our decision to proceed with the completion of the Acquisition. We expect to continue to hold the assets or equity interests of GRAIL separate until the applicable legal and regulatory proceedings are completed or, if required, a divestment of GRAIL is effected, and such inability to integrate may materially and adversely affect or prevent the synergies and other benefits we expect to achieve as a result of the Acquisition and could result in additional costs or liabilities, loss of revenue and other adverse effects on our business, financial condition and results of operations. In the second fiscal quarter of 2022, we accrued $453 million in anticipation of a potential Article 14(2)(b) Fine, included in accrued liabilities, representing 10% of our consolidated annual revenues for fiscal year 2021 in accordance with ASC 450, ~~Contingencies. In~~ addition, under applicable accounting rules, we may be required from time to time to perform

~~Table of Contents~~

interim analyses of the value of GRAIL. To the extent that the value of GRAIL on a standalone basis is less than its book value, we would be required to record an impairment on our consolidated financial statements.

~~Adverse economic or market conditions may harm our business.~~

Worsening economic conditions, including inflation, increasing interest rates, decreasing economic activity, volatility in equity and credit markets or other changes in the economic environment, may adversely affect our business, financial condition, or results of operations. For example,Furthermore, we depend on third-party manufacturers and suppliers for some of our products, or sub-assemblies, components, and materials used in our products, and the suppliers of these inputs may seek to raise prices in the current inflationary economic environment. If our costs increase and we are unable to successfully pass along those increased costs to our customers, our revenue and or operating profitability may be adversely affected. In addition, we have ~~a variable-interest-rate credit facility (see “Note 4. Debt~~”), under which we have no currently outstanding debt, and we may in the future raise additional debt or refinance existing debt. Our cost of borrowing in the future may be higher than it has been to date because interest rates have risen and may continue to ~~increase. An increased cost~~become subject to stockholder inspection demands under Delaware law, investigations initiated by regulators and law firms, and derivative or other similar litigation that can be expensive, divert management attention and human and financial capital to less productive uses and result in potential reputational damage. The GRAIL acquisition and subsequent litigation resulted in (i) the announcement of ~~borrowing~~an investigation by the SEC and others by law firms of possible securities law violations; (ii) stockholder inspection demands seeking to investigate possible breaches of fiduciary duties, corporate wrongdoing or a lack of independence of the members of the Board; and (iii) the filing of a stockholder derivative and class action complaint captioned Icahn Partners LP, et al. v. deSouza, et al.. The complaint, purportedly brought on behalf of Illumina and public holders of Illumina’s common stock, was filed in the Delaware Court of Chancery against certain current and former directors (including our former Chief Executive Officer). We are named as a nominal defendant in the complaint. The lawsuit alleges the named directors breached their fiduciary duties by knowingly causing Illumina to unlawfully close the GRAIL acquisition, concealing material facts related to the GRAIL acquisition and making inadequate disclosures. See note “7. Legal Proceedings” for further details. In the event that any of the matters described above result in one or more adverse judgments or settlements, we may ~~adversely affect~~experience an adverse impact on our financial condition, ~~and~~ results of ~~operations.~~operations or stock price.

SHARE REPURCHASES AND SALES

Purchases of Equity Securities by the Issuer

None during the quarterly period ended October ~~2, 2022.~~1, 2023.

Unregistered Sales of Equity Securities

None during the quarterly period ended October ~~2, 2022.~~1, 2023.

ADOPTIONS, MODIFICATIONS OR TERMINATIONS OF TRADING PLANS

During the quarterly period ended October 1, 2023, the following directors and officers adopted, modified or terminated 10b5-1 plans:

•On September 26, 2023, Phil Febbo, our former Chief Medical Officer, terminated a trading arrangement he had previously adopted with respect to the sale of securities of the Company’s common stock (a “Rule 10b5-1 Trading Arrangement”) in connection with his departure from the Company. Mr. Febbo’s Rule 10b5-1 Trading Arrangement was adopted on May 30, 2023, had a termination date of December 31, 2024, and provided for the sale of up to 9,294 shares of common stock pursuant to the terms of the plan.

Other than as disclosed above, during the quarterly period ended October 1, 2023, (i) none of the Company’s directors or officers adopted or terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” and (ii) the Company did not adopt a “10b5-1 trading arrangement,” in each case as such term is defined in Item 408 of Regulation S-K.

4342

Table of Contents

EXHIBITS

Incorporated by Reference

Exhibit Number

Exhibit Description

Form

File Number

Exhibit

Filing Date

Filed Herewith

+10.1

O ffer Letter to Jacob Thaysen, dated August 31, 2023

8-K

001-35406

10.1

9/5/2023

+10.2

A mended and Restated Offer Letter to Jacob Thaysen, dated November 8, 2023

8-K

001-35406

10.3

11/9/2023

+10.3

S eparation Agreement and Release of All Cl aims by and between Illumina, Inc. and Phil Febbo, dates as of September 5, 2023

31.1

Certification of ~~Francis A. deSouza~~Jacob Thaysen pursuant to Section 302 of the Sarbanes-Oxley Act of ~~2002.~~2002

31.2

Certification of Joydeep Goswami pursuant to Section 302 of the Sarbanes-Oxley Act of ~~2002.~~2002

32.1

Certification of ~~Francis A. deSouza~~Jacob Thaysen pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of ~~2002.~~2002

32.2

Certification of Joydeep Goswami pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of ~~2002.~~2002

101.INS

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

XBRL Taxonomy Extension Schema

101.CAL

XBRL Taxonomy Extension Calculation Linkbase

101.LAB

XBRL Taxonomy Extension Label Linkbase

101.PRE

XBRL Taxonomy Extension Presentation Linkbase

101.DEF

XBRL Taxonomy Extension Definition Linkbase

104

Cover Page Interactive Data File - formatted in Inline XBRL and included as Exhibit 101

+ Management contract or corporate plan or arrangement

* Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the SEC upon request.

4443

Table of Contents

FORM 10-Q CROSS-REFERENCE INDEX


			Page
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements			6
Condensed Consolidated Balance Sheets			6
Condensed Consolidated Statements of Operations			7
Condensed Consolidated Statements of Comprehensive ~~Income (Loss)~~Loss			8
Condensed Consolidated Statement of Stockholders’ Equity			9
Condensed Consolidated Statements of Cash Flows			11
Notes to Condensed Consolidated Financial Statements			12
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			3129
Item 3. Quantitative and Qualitative Disclosures About Market Risk			4039
Item 4. Controls and Procedures			4039

PART II. OTHER INFORMATION
Item 1. Legal Proceedings			4039
Item 1A. Risk Factors			4039
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			4342
Item 3. Defaults Upon Senior Securities			None
Item 4. Mine Safety Disclosures			Not Applicable
Item 5. Other Information			~~None~~42
Item 6. Exhibits			4443
Signatures			4645

4544

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		ILLUMINA, INC. (registrant)

Date:	November ~~3, 2022~~9, 2023
		By:	/s/ Joydeep Goswami
		Name:	Joydeep Goswami
		Title:	Chief Financial Officer, Chief Strategy and Corporate Development Officer ~~and Interim Chief Financial Officer~~

4645